Devices and methods for trans-scleral subretinal drug delivery

The device with a side-firing, two-stage needle assembly addresses the invasiveness and complications of current subretinal delivery methods by providing precise and controlled delivery to the subretinal space, reducing procedural risks and invasiveness.

WO2026232232A1PCT designated stage Publication Date: 2026-11-12DRAGONFLEYE THERAPEUTICS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050658
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current methods of subretinal drug delivery, such as trans-vitreal and suprachoroidal approaches, are highly invasive and carry significant risks and complications, including retinal tears, detachment, hemorrhage, and variability in drug delivery volume, making it challenging to safely deliver therapeutic substances to the subretinal space, especially at posterior locations.

Method used

A device with a side-firing needle configuration and a two-stage needle assembly, where the outer needle penetrates the sclera and choroid, and the inner needle is deployed to reach the subretinal space, allowing precise delivery and removal of substances with minimal invasiveness, using mechanisms like bipolar diathermy and energy delivery to facilitate tissue penetration.

Benefits of technology

The device enables safe and precise delivery of therapeutic substances to the subretinal space with reduced risk of complications, eliminating the need for vitrectomy and improving accuracy and control over the delivery volume, suitable for in-office procedures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2026050658_12112026_PF_FP_ABST
    Figure CA2026050658_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Devices and methods are described for using at least one needle for injecting into and / or removing substances from a target. For example some devices comprise a housing defining a main body with a first longitudinal axis and a distal end portion of the device having a second longitudinal axis; a two-stage needle in the housing and moveable for deployment at the distal end portion where the two-stage needle has an inner needle that is disposed within an outer needle; and a needle drive assembly that is coupled to the two-stage needle, the needle drive assembly being configured to cause the outer needle to extend through a needle exit location on a lateral contact surface of the distal end portion of the device at an angle to the longitudinal axis of the distal end portion of the device, and to cause the inner needle to extend through the outer needle during needle deployment.
Need to check novelty before this filing date? Find Prior Art

Description

TITLE: Devices and Methods for Trans-scleral Subretinal Drug Delivery Cross Reference to Related Application

[0001] This application claims the benefit of U.S. Provisional Patent Application No.63 / 800,304, filed May 5, 2025, the entire contents of which are incorporated herein by reference.FIELD

[0002] The various embodiments described herein generally relate to devices for penetrating into the eye to access internal layers, structures, spaces, or other targets, such as, but not limited to, the subretinal space, for delivery of various treatments including fluids, gases, drugs, gene therapies, cell suspensions, and other therapeutics substances and / or for the removal of substances.BACKGROUND

[0003] The following paragraphs are provided by way of background to the present disclosure. They are not however an admission that anything discussed therein is prior art or part of the knowledge of a person of skill in the art.

[0004] Subretinal drug delivery involves placement of a drug or other material into the space between the retina and the retinal pigment epithelium (RPE) in the eye. The retina is the part of the eye containing photoreceptors which convert light into electrical signals which then travel through the optic nerve to the brain. The choroid is the vascular layer below the retinal pigment epithelium which supplies the outer retina and RPE with oxygen and nutrients. The retina and RPE layers are normally in contact with each other; however, the subretinal space is a potential space between these two layers which can be opened by fluid pressure.

[0005] Subretinal injection is the preferred route of administration for stem cell and gene therapies for the treatment of a variety of vision-threatening conditions affecting the retina. Subretinal injections have multiple advantages over intravitreal injections, topical delivery, or other routes of administration due to higher concentrations of the therapeutic agent reaching the target tissue with lower doses and reduced risk of systemic immune response or inflammation since the subretinal space is an immune-privileged environment. In the case of cell-based therapies, injecting in the subretinal space without leakage of material into the vitreous cavity has the potential advantage of avoiding vitreous or pre-retinal membrane formation.

[0006] There are two types of gene therapies that are delivered via viral vectors. The first type uses the viral vector to transfect a cell and convert it into a biofactory for an antibody, protein, drug or other substance. For example, there are treatments where a single gene administration can cause the target cells to produce antibodies to VEGF. This can provide extended treatment-free periods and replace the need for frequent intravitreal injections every 1-2 months. These gene therapies, when given subretinally are injected in the peripheral subretinal space as conversion of cells to a biofactory can eventually cause the cells to burn out and stop functioning, which has minimal visual impact when in the periphery. The other type of gene therapy involves gene augmentation or gene replacement in patients with a retinal dystrophy. This often requires injecting the gene therapy in the subretinal space in the macular region. The macula is a circular region of the retina approximately 5 mm in diameter which is essential to high resolution, detailed vision.

[0007] Unfortunately, present methods of subretinal delivery are highly invasive and carry unwanted complications and side effects for the patient. The two main methods which currently exist are via a trans-vitreal approach using pars plana vitrectomy and via suprachoroidal catheterization followed by axial deployment of a needle through the choroid.

[0008] The current standard of care for gene therapy delivery is the trans-vitreal approach. With this method, patients, including children, have to have anesthesia (sometimes a general anesthesia) and undergo a procedure called a pars plana vitrectomy. In pars plana vitrectomy, three incisions are made at the front of the eye to insert trocars through the sclera and choroid. The vitreous gel, which normally fills the eye, is removed and replaced with fluid, air, gas or silicone oil. This can be challenging in younger patients where posterior vitreous separation can be more challenging to induce surgically and where there may be a higher risk of retinal tears and retinal detachment among others. Additionally, patients who undergo vitrectomy also will often develop a cataract in the 6-12 months following the procedure which will often require subsequent cataract surgery. Following completion of the vitrectomy, a very small gauge cannula (38-41 G) is inserted through one of the trocars and used to puncture the retina and then inject the material into the subretinal space. During this injection, some of the material may unintentionally be injected into the vitreous cavity before the subretinal bleb forms. Even after the subretinal bleb forms, recent studieshave shown that some material refluxes out of the bleb due to the hole in the retina and the injection pressure. This raises the risk of adverse events related to inflammation or other interaction of the material with off-target tissue. This also adds substantial variability to the exact volume of material delivered to the subretinal space, which is problematic for dosing of a drug solution or other therapeutic.

[0009] The second current main method of subretinal delivery, which has been studied but not yet used commercially, is suprachoroidal catheterization. The suprachoroidal space is the potential space between the sclera and choroid. The “Orbit Subretinal Delivery System” [1], which has been FDA cleared, takes a suprachoroidal catheterization approach to reach the posterior of the eye and then axially deploys a curved microneedle through the choroid and into the subretinal space. Suprachoroidal catheterization is a complicated procedure which requires a scleral incision and risks hemorrhage caused by tunneling through the suprachoroidal space.

[0010] Because of all of these challenges, there is a need for a subretinal delivery system that safely delivers a desired volume into the subretinal space, including at posterior locations of the eye.SUMMARY OF VARIOUS EMBODIMENTS

[0011] In accordance with the teachings herein, in one aspect there is provided a method of subretinal injection comprising: positioning a device against the outer scleral tissue of a posterior segment / region of the eye ; advancing at least one needle through the sclera to a subretinal space of the eye, and delivering a therapeutic substance into the subretinal space through the at least one needle or removing a substance from the subretinal space through the needle.

[0012] Likewise, in another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a device for injecting into and / or removing substances from a target, wherein the device comprises: a housing defining a main body and a distal end portion of the device; at least one needle that is moveable and deployable at the distal end portion of the device at an angle to a longitudinal axis of the distal end portion of the device during needle deployment in a side firing configuration.

[0013] In another aspect, in accordance with the teachings herein in at least one embodiment, the needle drive assembly comprises a control element that is actuatableby a user; and a needle holding member that is disposed within the housing and coupled to the control element, the needle holding member being moveable about a pivot point and holding at least one needle, the needle being located at a distal end portion of the needle holding member, wherein the user actuates the control element to extend and retract the needle, wherein the pivot point is an actual pivot or a virtual pivot created through actuation mechanics of the needle holding member.

[0014] In another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a device for injecting into and / or removing substances from a target, wherein the device comprises a housing defining a main body with a first longitudinal axis and a distal end portion of the device having a second longitudinal axis; a two-stage needle that is in the housing and moveable for deployment at the distal end portion of the device, the two-stage needle having an inner needle and an outer needle, the inner needle being disposed within the outer needle; and a needle drive assembly that is coupled to the two-stage needle, the needle drive assembly being configured to cause the outer needle to extend through a needle exit location on a lateral contact surface of the distal end portion of the device at an angle to the longitudinal axis of the distal end portion of the device, and to cause the inner needle to extend through the outer needle during needle deployment.

[0015] In at least one embodiment, the needle drive assembly comprises: a primary control element that is actuatable by a user; and a needle holding member that is disposed within the housing and movably coupled to the primary control element, the needle holding member being adapted to hold the outer needle and being moveable during needle deployment to move the outer needle when the primary control element is actuated by the user to extend and retract the outer needle.

[0016] In at least one embodiment, the needle holding member is moveable about a pivot point that is an actual pivot or a virtual pivot and wherein the pivot point is located such that a portion of a perimeter of a circle that is concentric with the pivot point is tangent to the outer needle and coincident to an entry point where the outer needle enters the target.

[0017] In at least one embodiment, the inner needle and the outer needle are independently moveable.

[0018] In at least one embodiment, the target is a subretinal space of an eye and, during use, the outer needle is extended to penetrate a scleral layer of the eye to pushagainst a choroid of the eye, the inner needle is then extended through the outer needle to penetrate through the choroid of the eye into the subretinal space, the outer needle is then retracted, and the inner needle is then advanced within the subretinal space before injection and / or removal.

[0019] In at least one embodiment, a distal end portion of the inner needle is precurved, the inner needle optionally being made of a super-elastic material which is heat set to a curved shape, allowing it to be straight when retracted inside the outer needle and return to its curved shape upon deployment outside of the outer needle, wherein the super-elastic material is optionally nitinol.

[0020] In at least one embodiment, an insulating material is disposed between the inner needle and the outer needle to electrically isolate the inner needle from the outer needle, the insulating material comprising an insulating sleeve, a coating, or a combination thereof.

[0021] In at least one embodiment, the inner needle and the outer needle are electrically coupled to a voltage generator to operate as a bipolar electrode pair for delivering high-frequency electrical energy at tips of the needles during bipolar diathermy where current flows from one of the needles through intervening tissue and returns via another of the needles.

[0022] In at least one embodiment, wherein the voltage generator is configured to apply diathermy energy before or during needle advancement through scleral or choroidal tissue for preconditioning thereby facilitating easier passage for at least one of the needles through the preconditioned tissue.

[0023] In at least one embodiment, the device is operable in a bipolar diathermy mode or a monopolar diathermy mode, wherein during monopolar diathermy one of the inner needle and the outer needle is adapted to be an active electrode and a dispersive return electrode is positioned at a remote location on the patient’s body.

[0024] In at least one embodiment, the needle drive assembly comprises a secondary control wheel that is user actuatable, a follower free-spinning backup wheel that rotates on an axle attached to a body of the device, and a friction drive wheel that is coupled to the secondary control wheel and spaced apart from the follower free-spinning backup wheel so that a proximal portion of the inner needle is slidably received between the follower free-spinning backup wheel and the friction drive wheelso that actuation of the secondary control wheel moves the inner needle within the outer needle.

[0025] In at least one embodiment, the needle drive assembly comprises a secondary control wheel that is user actuatable, a gear that is attached to or integral with the secondary control wheel, a follower gear that interfaces with the gear at the control wheel and has a nut at a center of the follower gear, and a lead screw having a conduit through which a proximal portion of the inner needle is coupled so that the inner needle moves as the lead screw moves, wherein the nut is disposed to travel on the lead screw, wherein when the second control wheel is turned the gear at the control wheel imparts rotation on the follower gear and the nut at the center of the follower gear causes the lead screw and the inner needle to move axially.

[0026] In at least one embodiment, the device comprises a secondary control wheel that is user actuatable to move the inner needle, and the needle drive assembly further comprises: a follower free-spinning backup wheel that rotates on an axle attached to a body of the device; a friction drive wheel that is coupled to the control wheel; a pushing body that is slidably disposed between the free-spinning backup wheel and the friction drive wheel and having a helical thread on its outer cylindrical surface; a back-drivable screw or cam follower that is coupled to and downstream of the pushing body; and a nut or cam attached to the device body and in contact with the back-drivable screw, wherein the back-drivable screw is caused to rotate by the nut or the cam when the back-drivable screw is axially moved by the friction drive wheel when rotated by the control wheel, and wherein the inner needle is attached to the back-drivable screw or the cam follower so that the inner needle will move axially and twist when actuated by the screw or the cam follower.

[0027] In at least one embodiment, the device further comprises a secondary control wheel that is user actuatable and coupled to a helical gear tooth wheel and the needle drive assembly further comprises: a driven helical gear that is coupled to the helical gear tooth wheel such that the driven helical gear and the helical gear tooth wheel are right-angle helical gears and the driven helical gear is coupled to a back-drivable screw and nut with the inner needle being coupled to the driven helical gear and the back-drivable screw such that rotation of the secondary control drives the inner needle both axially and rotationally.

[0028] In at least one embodiment, the needle drive assembly comprises a motor that is electrically coupled to and controlled by a controller, wherein the motor is configured to drive the inner needle axially and / or rotationally during extension or retraction.

[0029] In at least one embodiment, a drive gear of the needle drive assembly has an involute spline and the motor has an output with a pinion gear that is adapted to engage the involute spline.

[0030] In at least one embodiment, the motor has an output gear that is coupled to a driven gear having a coupled screw body that passes through a stationary support block with a threaded channel and the inner needle is axially coupled to the coupled screw body so that rotation of the output gear causes the coupled screw body to translate axially while simultaneously rotating, thereby advancing and rotating the inner needle.

[0031] In at least one embodiment, the needle drive assembly is configured to simultaneously rotate and axially advance the inner needle during deployment, such that the inner needle follows a helical path as it is extended or retracted.

[0032] In at least one embodiment, the distal end portion of the inner needle has a needle tip geometry which is axially symmetric.

[0033] In at least one embodiment, the device further comprises a vial, a plunger that is in fluid communication with the vial and a motor that controls the plunger motion, wherein during use a proximal end of the inner needle is adapted to penetrate the vial and transport a treatment fluid to the inner needle when the vial contains the treatment fluid or remove a substance from the target and transport the substance to the vial when the vial is empty.

[0034] In at least one embodiment, a proximal end portion of the inner needle is flu idically coupled to a vial to receive a treatment fluid to deliver when the distal end portion of the inner needle is deployed.

[0035] In at least one embodiment, an upper region of the inner needle has a flexural section allowing for a proximal end of the inner needle to be fixed in place.

[0036] In at least one embodiment, the device comprises a trocar or blade at a distal end of the device for performing an incision while the device is moved into position before the outer needle or the inner needle is deployed.

[0037] In at least one embodiment, the device comprises a vibrating element that is configured to apply a vibration to a distal needle portion of the inner or outer needles.

[0038] In at least one embodiment, a bevel of a needle tip of the inner needle is oriented away from a center of the target prior to the needle tip penetrating a surface of the target, and as the inner needle tip penetrates the surface of the target, the bevel is rotated to be oriented towards the center of the target.

[0039] In at least one embodiment, the device is configured to provide cryotherapy, or other energy delivery through the inner needle and / or the outer needle.

[0040] In another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a device for trans-scleral access to the eye of a patient, the device comprising: a housing defining a main body and a distal end portion; at least one needle that is moveable for deployment at the distal end portion of the housing to penetrate through a scleral layer of the eye to access an internal target of the eye; and a needle drive assembly coupled to the at least one needle and configured to cause the at least one needle to extend through a needle exit location on a lateral contact surface of the distal end portion of the housing, wherein the at least one needle is conductive and coupled to an energy source that is configured to deliver energy through or from the at least one needle to coagulate, modify, or ablate tissue adjacent to an exposed conductive portion of the at least one needle that has been deployed to penetrate the eye.

[0041] In at least one embodiment, the at least one needle is coupled to the energy source to provide monopolar diathermy, wherein the at least one needle is configured as an active electrode for delivering high-frequency electrical energy to the tissue, and a dispersive return electrode is positioned ata remote location on a body of the patient.

[0042] In at least one embodiment, the energy source is configured to provide radiofrequency energy to the exposed conductive portion of the at least one needle to achieve the tissue ablation, coagulation, or modification.

[0043] In at least one embodiment, the device comprises a laserfiber or waveguide routed through a lumen of the at least one needle that is coupled to the energy source to deliver laser energy to the tissue at the exposed conductive portion of the at least one needle for photocoagulation or tissue cutting.

[0044] In at least one embodiment, the device further comprises a vibrating element coupled to a needle holding member that is disposed within the housing andis coupled to the at least one needle, the vibrating element being configured to induce oscillations in the needle holding member that are transmitted to a distal portion of the at least one needle, the oscillations being semi-axial vibrations that facilitate penetration of the tip of the at least one needle through tissue.

[0045] In at least one embodiment, the vibrating element comprises a piezoelectric transducer coupled to the needle holding member, the piezoelectric transducer being configured to deliver ultrasonic energy through the at least one needle to facilitate tissue penetration or enhance drug delivery through sonoporation.

[0046] In at least one embodiment, the device comprises a cryogenic cooling element disposed within the housing and thermally coupled to a proximal or intermediate portion of the at least one needle to provide cooling thereto so that the at least one needle thermally conducts cryogenic thermal energy to tissue at or near the tip of the at least one needle for cryocoagulation of vessels at a needle entry site during use.

[0047] In at least one embodiment, the device comprises a resistive heating element disposed at or near a distal end of the at least one needle for delivering controlled thermal energy to tissue adjacent to the distal end of the at least one needle.

[0048] In at least one embodiment, energy delivered through the distal end portion of the at least one needle alters mechanical properties of tissue thereat to reduce mechanical resistance to needle deployment into the tissue.

[0049] In another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a device for penetrating into a target at a posterior region of the eye, the device comprising: a housing defining a main body and a distal end portion; at least one needle that is moveable and deployed at the distal end portion in a side-firing configuration; a needle drive assembly coupled to the at least one needle and configured to cause the at least one needle to extend through a needle exit location on a lateral surface of the distal end portion of the device; and an end effector for conjunctiva management during use, the end effector being disposed at or near the distal end portion of the device for displacing or incising the conjunctiva to allow for passage of the distal end portion of the device to more posterior regions of the eye before the at least one needle is deployed.

[0050] In at least one embodiment, the end effector comprises a trocar integrated into the distal end portion of the housing, the trocar being shaped as one of a pyramidal trocar, a conical trocar, or a conical trocar with a flat face.

[0051] In at least one embodiment, the trocar has a length of approximately 1 to 10 mm.

[0052] In at least one embodiment, the end effector comprises a blade that is moveable at a distal tip of the device between an extended position and a retracted position using an actuator that is mechanically coupled to the blade.

[0053] In at least one embodiment, the blade is oriented so that a flat plane of the blade is tangent with the eye to reduce likelihood of cutting a sclera of the eye or an eyelid of the eye.

[0054] In at least one embodiment, the device further comprises a spring-loaded cover at the distal tip of the device, wherein the cover is deflected to expose the blade when the device tip is pressed against the conjunctiva and the cover returns to a rest position to conceal the blade when a force is removed from the device tip.

[0055] In at least one embodiment, the end effector comprises a suction element for lifting a portion of the conjunctiva and a cutting element for incising the lifted conjunctiva.

[0056] In at least one embodiment, the end effector is an expandable trocar that is separate from the housing of the device, has a sharp distal tip and a flexible expandable body with a lumen wherein the flexible expandable body has a collapsed configuration for initial puncturing of the conjunctiva with the sharp distal tip and an expanded configuration after the initial puncturing occurs during which the flexible expandable portion is radially expanded when the distal end portion of the device is inserted through the lumen.

[0057] In at least one embodiment, the trocar is adapted to remain stationary relative to the conjunctiva after the initial puncturing and during passage of the distal end portion of the device, and the sharp tip of the trocar is sized to result in a smaller residual wound in the conjunctiva compared to a direct incision sized for the distal end portion of the device.

[0058] In at least one embodiment, the flexible expandable portion comprises a stent-like structure made from a shape-memory alloy exhibiting superelastic behaviorto return to the collapsed configuration upon withdrawal of the distal end portion from the trocar.

[0059] In another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a needle for insertion into a target, wherein the needle comprises: a shaft having an inner lumen; and a tip at a distal end of the shaft, the tip having a needle tip geometry such that a bevel opening is shaped so that a bevel opening length spans only a single tissue layer at a time at the target after needle deployment.

[0060] In at least one embodiment, the needle tip has a combined conical and bevel needle tip geometry, creating a shorter bevel opening length while maintaining a sharp tip for tissue penetration.

[0061] In at least one embodiment, the needle tip geometry has sidewalls with a conical shape, a closed end and one or more holes or ports at one or more side locations sidewalls so that the needle tip only allows for fluid flow at the one or more holes or ports.

[0062] In at least one embodiment, the at least one needle comprises an outer needle and an inner needle disposed within the outer needle, and the needle tip geometry is at the distal end of the inner needle.

[0063] In another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a use of a device for treatment of a suprachoroidal or sub-retinal region of an eye, wherein the device is defined according to any one of embodiments described herein.

[0064] In these uses, the target is a portion of the eye including the suprachoroidal or sub-retinal region.

[0065] It will be appreciated that the foregoing summary sets out representative aspects of embodiments to assist skilled readers in understanding the following detailed description. Other features and advantages of the present application will become apparent from the following detailed description taken together with the accompanying drawings. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the application, are given by way of illustration only, since various changes and modifications within the spirit and scope of the application will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS

[0066] For a better understanding of the various embodiments described herein, and to show more clearly how these various embodiments may be carried into effect, reference will be made, by way of example, to the accompanying drawings which show at least one example embodiment, and which are now described. The drawings are not intended to limit the scope of the teachings described herein.

[0067] FIG. 1 is an anatomical drawing of the relevant structures of the eye.

[0068] FIG. 2 shows a side view of two different example embodiments of a device having distal end portions with different arc angles to reach more equatorially or more posteriorly on the globe of the eye depending on the target area.

[0069] FIG. 3 is a side view of an example embodiment of a device that actuates a needle with a pivoting needle holding memberwhich has a large arc angle for posterior injection such as posterior subretinal injection.

[0070] FIGS. 4A-4B illustrate different placements of a pivot point with respect to the needle for needle deployment at various needle exit angles ranging from approximately 60 to 120 degrees.

[0071] FIGS. 5A-5C illustrate several example embodiments of needle architectures for reducing or minimizing the outer diameter of the needle that enters the eye while maintaining adequate resistance to bending or buckling and reducing fluid resistance compared to a single long, small diameter needle.

[0072] FIGS. 6A-6B show a comparison between a standard beveled needle and an example embodiment of a combined conical and beveled needle tip geometry.

[0073] FIGS. 7A-7B show example embodiments of a closed-tip conical needle with one or more side ports and a conical needle with a hole at the needle tip.

[0074] FIG. 8 shows deflection (tenting) of the choroid and retina away from a needle tip as the needle tip is advanced through the sclera from outside the eye.

[0075] FIG. 9 illustrates an example schematic of a device having a vibrating actuator coupled to a needle holding member at a location to induce semi-axial vibration at the needle tip during penetration.

[0076] FIG. 10 shows an example of a two-stage needle embodiment in which, after the outer needle is deployed / extended and tents the choroid and retina, a smaller nested inner needle is deployed / extended axially to puncture the choroid and reach the subretinal space.

[0077] FIG. 11 shows an example of an alternative embodiment of a two-stage needle where the smaller nested inner needle is pre-curved so that after puncturing the choroid it advances tangentially within the subretinal space, forming a subretinal bleb between the retina and the choroid that is distal or spaced apart, by a target penetration depth, from the point of choroidal penetration.

[0078] FIGS. 12A-12B show example embodiments of a device having a drive mechanism for actuating a two-stage needle assembly.

[0079] FIG. 13 shows another example embodiment of a device having a drive mechanism for actuating a two-stage needle assembly.

[0080] FIG. 14 shows another example embodiment of a device having a drive mechanism that produces simultaneous axial and rotational (“screw”) motion during deployment of a nested inner needle of a two-stage needle assembly.

[0081] FIG. 15 shows an example embodiment of a device having a drive mechanism that uses right-angle helical gears to produce simultaneous axial and rotational motion of an inner needle of a two-stage needle assembly.

[0082] FIG. 16 shows an example embodiment of device having an electronically controlled drive mechanism in which a motor / gearbox is used for deployment of a two-stage needle assembly.

[0083] FIG. 17 shows an example embodiment of a device having a manually controlled drive mechanism that uses a crankshaft mechanism for deployment of a two-stage needle assembly.

[0084] FIG. 18 shows an example embodiment of a device for deploying a microneedle patch onto the surface of the eye in an area that is not easily reached by other mechanisms.

[0085] FIGS. 19A-19C shows side, rear and perspective views of example embodiments of plastic trocars built into the tip of a device to cut through the conjunctiva of the eye, including a pyramidal trocar shape, a conical trocar shape, and a conical trocar with one side cut to create a flat face.

[0086] FIGS. 20A-20B show a side view and a rear view, respectively, of an example embodiment of a needle-deploying device having a retractable blade that extends from the distal end portion of the device to make a hole in the conjunctiva.

[0087] FIGS. 21A-21B show a portion of an example embodiment of a needledeploying device having a spring-loaded cover for a blade, showing a non-deflected cover and a deflected cover, respectively.

[0088] FIG. 22A shows an example embodiment of an expandable conjunctival trocar 2201 in a collapsed configuration while being inserted through the conjunctiva, and having a flexible expandable portion and a sharp distal tip for puncturing the conjunctiva.

[0089] FIG. 22B shows the expandable trocar of FIG. 22A in an expanded configuration with a needle deployment device having a distal end portion that is passed through the trocar and the flexible portion of the expandable trocar is expanded around the device to hold the conjunctiva open.

[0090] FIG. 23 shows a schematic cross-sectional view of an example embodiment of a device with a two-stage needle assembly that is configured for bipolar diathermy for delivering high-frequency electrical energy from an inner needle, after deployment, to adjacent tissue.

[0091] Further aspects and features of the example embodiments described herein will appear from the following description taken together with the accompanying drawings.DETAILED DESCRIPTION OF THE EMBODIMENTS

[0092] The headings and Abstract of the Disclosure provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.

[0093] Various embodiments in accordance with the teachings herein will be described below to provide examples of at least one embodiment of the claimed subject matter. No embodiment described herein limits any claimed subject matter. The claimed subject matter is not limited to devices, systems or methods having all of the features of any one of the devices, systems or methods described below or to features common to multiple or all of the devices, systems or methods described herein. It is possible that there may be a device, system or method described herein that is not an embodiment of any claimed subject-matter. Any subject matter that is described herein that is not claimed in this document may be the subject matter of another protective instrument, for example, a continuing patent application, and theapplicants, inventors or owners do not intend to abandon, disclaim or dedicate to the public any such subject matter by its disclosure in this document.

[0094] Furthermore, it will be appreciated that for simplicity and clarity of illustration, where considered appropriate, reference numerals may be repeated among the figures to indicate corresponding or analogous elements or steps. In addition, numerous specific details are set forth in order to provide a thorough understanding of the embodiments described herein. However, it will be understood by those of ordinary skill in the art that the embodiments described herein may be practiced without these specific details. In other instances, well-known methods, procedures and components have not been described in detail so as not to obscure the embodiments described herein. Also, the description is not to be considered as limiting the scope of the embodiments described herein.

[0095] It should also be noted that the terms “coupled” or “coupling” as used herein can have several different meanings depending on the context in which these terms are used. For example, the terms “coupled” or “coupling” can have a mechanical, electrical, thermal, pneumatic or fluidic connotation; such as indicating that two elements or devices can be directly connected to one another or connected to one another through one or more intermediate elements or devices via an electrical element, an electrical signal, a light signal or a mechanical element depending on the particular context.

[0096] Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to”.

[0097] It should also be noted that, as used herein, the wording “and / or” is intended to represent an inclusive-or. That is, “X and / or Y” is intended to mean X or Y or both Xand Y, for example. As a further example, the phrases “X, Y, and / or Z”, “any operable combination of X, Y and Z”, “X, Y, Z or any combination thereof” or “any combination of X, Y and Z” is intended to mean any of the following which are operable: X, Y, Z, X and Y, X and Z, Y and Z, orX, Y and Z.

[0098] It should be noted that terms of degree such as “substantially”, “about” and “approximately” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree mayalso be construed as including a deviation of the modified term, such as by 1%, 2%, 5%, 10% or 15%, for example, if this deviation does not negate the meaning of the term it modifies.

[0099] Furthermore, the recitation of numerical ranges by endpoints herein includes all numbers and fractions subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also to be understood that all numbers and fractions thereof are presumed to be modified by the term “about” which means a variation of up to a certain amount of the number to which reference is being made if the end result is not significantly changed, such as 1%, 2%, 5%, 10% or 15%, for example.

[0100] It should be noted that, as used herein, terms such as proximal and distal with respect to a device or a component in the device are defined with respect to the operator (e.g., human or robotic) contact point of the devices described herein. Accordingly, an upper portion of a handle of the device is referred to as a proximal portion of the device while an end portion of the device with a needle that is inserted into a physiological structure is referred to as a distal portion of the device.

[0101] In addition, it should be noted that the term distal portion ordistal end portion of a device or an element of a device is meant to cover a distal end region of the device or the element and is not limited to the very distal tip of the device or the element. Accordingly, components that are located at the distal end portion of a device or an element does not mean that those components are limited to being located at the very distal tip of the device or the element.

[0102] Further, it should be noted that the term proximal portion or proximal end portion of a device or an element of a device is meant to cover a proximal end region of the device or the element and is not limited to the very proximal tip of the device or the element. Accordingly, components that are located at the proximal end portion of a device or an element does not mean that those components are limited to being located at the very proximal tip of the device or the element.

[0103] As mentioned while there are two main approaches to subretinal delivery, there is a third emerging approach to subretinal delivery, which has not yet been used commercially, is a trans-scleral approach, in which a needle is used to access the subretinal space from the outside of the eye through the sclera from behind the retina, e.g., from a generally posterior outside surface of the eye, rather than through thevitreous cavity that is in front of the retina. A trans-scleral approach avoids the vitrectomy and the intraocular manipulation associated with the trans-vitreal standard of care and therefore has the potential to be significantly less invasive, to reduce procedure time, and to lower the risk of complications and side-effects. Some groups have investigated trans-scleral subretinal injection, for example using microneedles inserted through the sclera at or near the pars plana region [2], [3], However, these approaches are generally limited to accessing the anterior subretinal region and cannot reliably place a subretinal bleb in the posterior region where the macula and fovea are located (which are the primary targets for gene therapies treating conditions such as atrophic age-related macular degeneration and inherited retinal dystrophies). The fovea is a tiny depression near the center of the macula.

[0104] The various device embodiments described herein may generally employ a side-firing needle architecture in which the needle exits from a lateral face of a device that may be shaped to reach behind an eye, similar in form to a scleral depressor where the lateral face also has a contact surface that contacts the outer surface of the eye. Therefore, the device may be placed against the exterior surface of the eye well posterior to the limbus, which is between the between the cornea, conjunctiva, and the sclera, and is a highly vascularized and pigmented region, and the needle deployed from the contact surface through the sclera at a controlled angle and depth to directly place a bleb at a target area in the posterior region of the subretinal space of the eye. Because the device contacts and stabilizes the eye wall at the point of injection, it provides a controlled platform for precise needle deployment through the thin posterior tissues. In some embodiments, the needle architecture may also be front-firing / end firing and / or the device may be placed to access a more anterior location of the eye.

[0105] A challenge that arises with any needle-based approach to the subretinal space, including the trans-scleral approach using conventional needles, as realized by the inventors, is the relationship between bevel opening length and the thin, layered anatomy of the eye. When approaching the subretinal space from outside the eye, the needle must traverse the sclera (approximately 500 to 1200 micrometers thick), the choroid (approximately 100 to 200 micrometers thick), and arrive at the subretinal space (a potential space) without penetrating the retina (200 to 300 micrometers thick). Conventional hypodermic needles employ a lancet or bevel tip geometry in which the bevel opening length, the axial distance over which the lumen is exposed, is typicallyon the order of one to several millimeters. Because this opening length exceeds the thickness of any single tissue layer, the bevel opening spans two or more layers simultaneously during penetration. This creates an uncontrolled fluid path between adjacent layers, increasing the risk of drug leakage into the choroid or vitreous rather than the intended subretinal space. Unfortunately, reducing the bevel angle to shorten the opening length compromises the sharpness of the needle tip, increasing insertion force and tissue trauma. Advantageously, the inventors have developed several embodiments of novel needle tip geometries that can achieve both a short bevel opening length and sufficient tip sharpness to penetrate ocular tissue with minimal force.

[0106] Another challenge of the trans-scleral needle approach to the subretinal space is the variation in physical properties, including elasticity and strength, of the tissue layers on both sides of the subretinal space. It can be difficult to design or select a needle and needle tip geometry which, when an insertion force is applied, can easily penetrate the tissue layers to reach the target location without penetrating the tissue layers beyond the target location. Increasing the sharpness of the needle will allow the needle to penetrate more smoothly but also increases the risk of overpenetration into a tissue layer beyond the target location. Decreasing the sharpness of the needle may make it difficult to penetrate even the required tissue layers (e.g., the tissue layers to be penetrated), and / or may cause those tissue layers to stretch until, as the insertion force increases, the necessary penetration force is achieved, at which point those tissue layers snap back into place, along with the deeper tissue layers, thus also resulting in overpenetration. Advantageously, the inventors have determined several embodiments which address this challenge.

[0107] Furthermore, when performing a procedure using a trans-scleral approach to reach the subretinal space at more posterior locations of the eye, the conjunctiva may present an additional obstacle. The conjunctiva is a thin, transparent mucous membrane that lines the inner surface of the eyelids and folds over to cover the anterior surface of the sclera. The conjunctiva serves a protective role by acting as a barrier against pathogens and debris and by contributing to the formation of a tear film. When an instrument / device must access the posterior regions of the eye, including the macula, the conjunctiva must be displaced or may even need to be incised to permit the instrument’s distal end portion to reach the target site on the posterior sclera.Conventionally, the conjunctiva is opened by a separate surgical step known as a conjunctival peritomy, in which the surgeon uses scissors or forceps to create a flap or opening in the conjunctiva before proceeding with the primary procedure. This additional step increases operative time, requires additional instruments, and creates a wound that must be managed post-operatively. Furthermore, manipulation of the conjunctiva with separate instruments introduces risk of tissue damage, particularly in the tight confines of the posterior orbit. Advantageously, the inventors have developed at least one device embodiment described herein which addresses the challenges posed by the conjunctiva.

[0108] In accordance with the teachings herein there are provided various embodiments of a device that has a needle delivery mechanism, which may also be referred to as a needle delivery assembly, that may be used in a procedure where the needle enters the eye through the sclera, at locations including, but not limited to, more posterior locations toward the back of the eye, and improves safety and / or efficacy for delivering treatments such as a desired volume of a treatment material such as a drug to internal layers, structures, spaces, or other targets such as the subretinal space. This may eliminate the need for vitrectomy and associated complications and morbidity, reduce the need for costly operating room time, reduce the risks of reflux into the vitreous and resulting inflammation, and may provide greater accuracy regarding the desired volume of treatment material being delivered. For example, an in-office trans-scleral delivery of drugs into the subretinal space is a giant step forward in ophthalmology where gene therapies and stem-cell treatments may be delivered in the future in contrast to using conventional techniques and conventional devices which require an operating room and are more invasive.

[0109] The various device embodiments described herein have a certain structural arrangement of components that enable a needle to reach the posterior subretinal space and inject fluid, preferably minimally invasively. These embodiments may also allow for removal of fluid from the subretinal space for drainage, such as, for example, the build-up of subretinal fluid which occurs in rhegmatogenous retinal detachment or exudative retinal detachment. The various embodiments may also enable access to anterior and equatorial locations, and other internal layers, structures, spaces, or other targets besides the subretinal space, such as the suprachoroidal and supraciliary spaces.

[0110] Referring now to FIG. 1, shown therein is an illustration of the various anatomical components of an eye 100 including an outer eye surface 107, a first layer consisting of the sclera 104, a subsequent inner layer provided by the choroid 102, a retina 101 on an inner surface of the choroid 102 and an inner volume called the vitreous 105. The optic nerve 106 is at the posterior aspect of the posterior segment near the posterior pole of the eye. The central part of the retina is the macula 110 which is the most important part of the retina 101 for fine vision. A subretinal space 103 is between the retina and the retinal pigment epithelium (RPE). The anterior portion of the eye 100 includes the cornea, iris, pupil and lens. The conjunctiva 108 extends past medial portions of the outer surface of the eye 100 where the equator 109 of the eye is located.

[0111] Throughout the description of the various devices herein, it should be noted that:- the terms “target area”, “target location”, “target region” or “target’ may be synonymous with one another and used interchangeably herein;- the term “side-firing” refers to a device having a needle deployment architecture that is arranged to deploy / extend the needle out of a side, lateral surface of a portion of the device where the side or lateral surface is an exterior surface of the device and is generally spaced apart and extends in the same general direction (e.g., may be somewhat quasi parallel) as a longitudinal axis of the portion of the device where the needle is deployed;- the term “end-firing” or “front-firing” refers to a device having a needle deployment architecture that is arranged to deploy / extend the needle out of an end face at a portion of the device where the end face is an exterior surface of the device and is generally intersected with a longitudinal axis of the portion of the device where the needle is deployed and with devices that are front-firing / end firing the devices are usually placed to access a more anterior location of the eye and not reach past the equator of the eye;- the term “distal” is used for a portion of a device or an element of a device described in the various embodiments herein are defined that is closer to the end portion of the device that a user will grasp during use; and- the term “proximal” is used for a portion of a device or an element of a device described in the various embodiments herein are defined that is closer to the“business” end portion of the device that is placed adjacent to the outer surface of the eye where one or more needles are extended or retracted during use.

[0112] Referring now to FIG. 2, shown therein are partial views of two devices 201 , 202 that may be used to insert a needle into a region of the eye. Various embodiments are possible for these devices such as those described U.S. patent application publication no. US-2025-0064635-A1 and PCT patent application no. PCT / CA2025 / 050544, the contents of both of which are incorporated herein by reference in their entireties. These devices 201, 202 generally have a distal end portion 201 d, 202d, identified with dashed ellipses, that can be slid beneath the eyelid of a patient and be used to depress a region of the eye while the needle is fully retracted within the body of the device without any needle exposed. Then a side-firing needle 203 may be deployed from a lateral surface LS of the distal end portion 201 d, 202d and advanced through the sclera 104 using a user-controlled input, where the user may be a surgeon.

[0113] The shape of the distal end portions 201 d, 202d of the devices 201 , 202 is rectangular with curved portions such as a curved end as with distal end portion 201 d or a curved body with a curved longitudinal axis as with distal end portion 202d. The shape of the distal end portions 201 d, 202d also has a low profile (e.g., small height) such that they can fit between the outer surface of the eye and the ocular bones 204.200 In these embodiments, there is also a tapering (decrease in width) for the distal end portion 201 d, 202d compared to the upstream, proximal regions of the devices 201 , 202 to allow for the distal end portions to fit between the outer surface of the eye and the ocular bones 204. In some embodiments, the distal end portions may have a profile that is about 2 to about 5 mm in height.

[0114] In at least some device embodiments, the longitudinal axis of the distal portion DPLA1, DPLA2 of devices 201, 202, respectively, is at an angle to the longitudinal axis of the device DLA1, DI_A2 of the device 201, 202. This allows the distal end portion of the device 201, 202 to “wrap around” a portion of the posterior location of the eye past the equator The further posterior that the distal end portion reaches such as for device 202 the smaller the angle between the longitudinal axes of the device DLA2 and the distal end portion DPLA2. In contrast, for device 201, the distal end portion 201 d does not extend to as far a posterior location on the eye as the device 202 and so the angle between the longitudinal axes DPLA1 and DLA1 is larger.

[0115] In addition, the side firing deployment of the needle 203 in the devices generally described herein also allows for the devices, such as devices 201 , 202 to be used to reach a target location that is anterior or posterior while as the needle 203 can be deployed such that it is aligned with the target location and traverses the minimum distance to reach the target location which reduces any damage to the eye during deployment. This needle actuation strategy allows precise placement of the needle 203, which may be guided by a light source 305 (e.g., see FIG. 3) transmitted from the device end portion 201, 203 which transilluminates a portion of the eye, such as the sclera. The user can use this light to assess the location of the device and its needle exit location relative to the target location for therapeutic delivery, or other treatment, when looking into the eye 100 through an indirect ophthalmoscope or widefield viewing system. Accordingly, the light source 305, or an external light source may be used by a user, such as a surgeon, to allow the surgeon to see the depth of the tip of needle 203 more easily within tissue. For example, an illuminating element located close to the needle exit location provide visualizations to the surgeon who may be looking into the eye through an indirect ophthalmoscope or ocular microscope to more easily determine where the needle tip will come out of the device as the contact surface of the device is being placed on an outer surface of the eye that is aligned with the target.

[0116] The needle 203 may be deployed such that the extent of which the needle extends (e.g., the “deployment length”) from the lateral surface LS of the distal end portion 203 of the device 201 , 202 is adjustable which allows the tip of the needle 203 to reach a desired location insertion depth for a target location within the eye. Accordingly, the desired insertion depth of the needle 203 is also adjustable based on the selected deployment length of the needle 203. For example, the adjustable deployment length of the needle 203 can be selected such that it is long enough to reach the subretinal space 103 of the eye 100 by making the maximum exposed needle length (e.g., the deployment length) outside the device body / housing at the LS / contact surface of the distal end portion approximately 1.5-3.5 mm.

[0117] Another aspect of the devices 201, 202 is that the curve of the distal end portion 203 may be selected not only to place the lateral surface of the distal end portion 203 adjacent the surface of the eye 100 but also to reach further back into the eye, such as close to or directly behind the macula, by increasing the length of this curved tip, which is referred to as the “arc angle” of the distal end portion. For example,where the device, such as device 202 is used to reach further posterior locations of the eye, the distal end portion 202d may have a larger curvature for the side having the LS (e.g., contact surface) that makes contact with the outer surface of the eye. In contrast, for device 201, the distal end portion 201 d does not extend to as far a posterior location on the eye as the device 202 and so curvature of the side having the LS (e.g., contact surface) that makes contact with the outer surface of the eye is smaller. For example, in FIG. 2, the distal end portion 201 d of the device 201 has a 15-degree arc angle while the distal end portion 202d of the device 202 has a 45-degree arc angle.

[0118] One way of achieving the needle deployment for distal end portions having different curvatures, e.g., different arc angles, is by adjusting a needle holding member in the interior of the devices 201, 202, as noted in PCT patent application no. PCT / CA2025 / 050544, to increase in length of curvature with the outer body of the device 202 in order to accommodate the increased arc angle, such as may be required for subretinal injections at ever increasing posterior locations of the eye relative to the equator 109. For example, FIG. 3 shows an example embodiment of a portion of a device 300 having a body / housing 302 and a distal end portion 202d that has a curved side upon which the surface LS that provides a contact surface sits. The device 300 also includes a control wheel 303 for extension and retraction of the needle 203 and a pivoting needle holding member 300nh with a proximal member 301 that is coupled to the control input wheel 303 and a distal member 306 that is coupled to the proximal member 301 via a pivot 304. The distal member 306 also has an arc angle that matches / follows the arc angle of the distal end portion 202d. The user may extend the needle 203 by adjusting a control input, such as by rotating the control input wheel 303, which has a spiral cam surface on an inner face (both not shown) that moves the proximal end of the pivoting needle holding member 300nh and causes rotation of the needle holder member 300nh about the pivot point 304. This structure and actuation method is described in further detail in PCT patent application no. PCT / CA2025 / 050544.

[0119] It should be noted that the various embodiments of the needle holding member and other components which are used to move the needle, so that the needle is extended (e.g., deployed) out of the device or retracted into the device, may bereferred to collectively as a needle drive assembly or a needle drive mechanism. Various example embodiments of needle drive assemblies are provided herein.Needle Actuation Mechanics

[0120] Changes to the angle at which the needle 203 exits the device’s lateral surface / contact surface where it contacts the eye can be made through adjustment of the internal actuating mechanics of the device. For example, the location of the pivot (either an “actual pivot” (e.g. real pivot)) in embodiments which use a physical pivot or a “virtual pivot” in embodiments which use a needle holding member that has a cantilever, flexure or pivot structure (e.g., FIG. 3)) determines a needle exit angle 403 as shown in FIGS. 4A-4B. The needle exit angle is the angle between the needle and a tangent line T at the surface of the eye where the needle is inserted.

[0121] In order for the needle to advance along its own starting axis, the needle and pivot point may be arranged such that a portion of a perimeter of a circle 401 concentric with the pivot point 304 is tangent to the needle 203 and coincident to an entry point 402 where the needle 203 enters the eye 100. FIG. 4A shows a lower portion of a device for one embodiment where the arc angle of the distal end portion of the device 202 is 45 degrees and the needle exit angle 403 is 90 degrees. FIG. 4B shows a lower portion of a device for another embodiment where the arc angle of the distal end portion of the device 202 is 45 degrees and the needle exit angle 403 is 110 degrees. It should be noted that the pivot point 304b is farther to the left of a longitudinal axis of the distal end portion of the device 201 for the case with the 110 degree exit angle than for the 90 degree exit angle where the pivot point 304a is farther to the right of a longitudinal axis of the distal end portion of the device 202. In both cases the distance from the needle 203 to the pivot point 304 is the same. Since the needle 203 is tangent to the concentric circle 401 about the pivot at the entry point 402 this allows for more of a tangential entry angle where the needle 203 enters the eye 100, as the needle 203 advances there will be minimal motion perpendicular to the longitudinal axis of the needle 203 at the entry point 402 (note the entry point 402 may also be referred to as an entry location, an insertion point or an insertion location) in order to minimize non-axial movement of the needle within the tissue. Other points on the needle 403 that are not at the entry point 402 may move perpendicularly due to the slight angling of the needle 403 from its original position as it pivots when it isfurther extended / retracted by the needle holding member 302 during actuation. Advantageously, this structural design and location of the pivot point reduces the amount of non-axial motion of different points of the needle 403 as it is extended, which reduces the possibility of tearing or stretching the tissue where the tip of the needle 403 is being inserted.

[0122] By selecting the pivot point location in space (up and down and side to side), with reference to the needle exit location, the angle at which the needle exits the device and enters the eye can be set over a wide angular range. The pivot location is preferably chosen such that a circle concentric with the pivot point can be drawn which is tangent to the needle 203 at the point of entry of the needle into the eye. This condition can be satisfied for a range of pivot distances from the needle 203 (radius of the concentric circle), and this radius can be chosen so that the beam (e.g., an element of the needle holding member) may be stiff enough to prevent significant deflection under needle insertion forces. Maintaining this condition aids in needle motion along its axis.

[0123] Another aspect of needle actuation that may be included in one or more device embodiments is any combination of selecting the angle of the needle when being inserted into the eye, the sharpness of the tip of the needle 203, the shape of the bevel of the needle 203 and the size of the bevel opening of the needle 203. These various parameters may be selected to improve the ease with which the needle tip penetrates various layers / tissues of the eye and / or the match between the location and / or size of the needle opening relative to the target location for improving the delivery of treatment fluid to the target location or removing fluid or other objects from the eye. This is further discussed in the section on needle design.

[0124] In another aspect, the curved distal portions of the devices may be selected such that the needle is angled back towards the proximal body of the device that is being held by the user, which allows the user to “reach around” the eye to reach ever increasing posterior locations of the eye for performing procedures on tissues or objects that are more directly accessible from posterior locations on the eye.Needle Design

[0125] When injecting drugs or other therapeutic fluids into the subretinal space, usually they are of low viscosity, allowing a very small inner diameter needle to beused without requiring very high injection forces. Smaller needles give the advantages of creating smaller holes in tissues which makes the procedure less painful for patients and imparts less damage to the tissues. Additionally, having a smaller diameter hole may allow for less leakage of the drug through the wound after the injection. Smaller diameter needles also have a shorter bore opening for the same bevel angle at the tip of the needle when compared to larger diameter needles. Thus, having a smaller needle decreases the likelihood of the needle bore being in both the subretinal and suprachoroidal (or choroidal) spaces at the same time and injecting fluid into both instead of preferentially injecting fluid into either the suprachoroidal or the subretinal space alone. In other words, a smaller needle increases the chances of the needle bore / opening being located in the target location (e.g., one type of tissue) rather than being in both the target location and another adjacent structure (e.g., the bore being in two adjacent tissue layers or two adjacent structures.

[0126] A challenge with reducing needle diameter is that when approaching the subretinal space 103 from outside of the eye, the needle must also pass through the sclera 104, which is a dense tissue that is harder to penetrate than another layer of the eye such as the choroid. Needles smaller than approximately 30-gauge tend to buckle when attempting to puncture the sclera. This can be combatted by making the needle diameter stepped in order to maintain high stiffness for a majority of the needle length, except for the distal end portion, and have the needle diameter only be thin at the very end of the needle.

[0127] For example, referring to FIG. 5A, shown therein are side and cross-sectional views of a two-stage nested needle 500a having two portions including a first portion / first stage that is a larger diameter outer needle 501 and a second portion / second stage that is a smaller diameter inner needle 502 that extends is disposed within the larger diameter outer needle and extends from the distal end of the outer needle. The inner needle 502 has a length that is sufficient to penetrate into the target location such as, for example, penetrating the sclera and choroid to reach the subretinal space. In some example embodiments, the first portion (i.e., a larger diameter portion) may be a 30-gauge bent needle 501, which may be used for a majority of the needle structure, and the second portion (i.e., a smaller diameter portion relative to the first portion) is shorter than the first portion and may be a 33- or 34-gauge needle 502 that may be located at the end of the needle and has a lengththat is about the same as the maximum exposed needle length plus about 30% to account for tissue thickness uncertainty which then also helps reduce the chance the user will insert the needle too far. For example, the length of the second portion 502 may be selected to be equal to the thickness of the final tissue layer or layers through which the needle 500a is expected to pass (i.e. the choroid, or the choroid and sclera combined) while the ‘shoulder’ formed where the second needle portion 502 extends past the first needle portion 501 prevents the second portion 502 from also penetrating the final tissue layer or layers. Buckling calculations indicate that a 33- or 34-gauge needle less than approximately 9 mm long can withstand expected axial needle insertion forces with a factor of safety of about two.

[0128] Referring now to FIG. 5B, shown therein are side and cross-sectional views of a single needle 500b in which the outer diameter is continuously tapered into a conical shape by grinding to reduce the diameter linearly along the needle length towards the distal end portion with the bore opening.

[0129] Alternatively, FIG. 5C shown therein are side and cross-sectional views of a single needle 500c where there is a relatively constant outer diameter in a first portion 504 after which the outer diameter necks down over a short length in a transition region 504t to a smaller outer diameter over a distal end portion 504d of the needle 500c.

[0130] In some embodiments, a gradually changing outer diameter needle, such as needle 503, 504 may be made from two discrete needles that are concentrically mated and glued or welded together, or the larger diameter portion of a needle may also be suaged or grinded down to a smaller diameter at the distal end portion near and tip of the needle, for example. The grinding or suaging can occur continuously along the length of the needle to make the needle conical in shape such as in regions 503, 504, or the change in diameter can happen over a small length with a significant portion of the distal end 504d at the smaller outer diameter.Combined Conical and Bevel Needle Tip and Closed Cone with Side Holes

[0131] Various embodiments of the devices described herein may employ a needle in which the needle tip has a combined conical and bevel geometry. Referring now to FIGS. 6A-6B, FIG. 6A shows perspective, isometric and cross-sectional views of a distal end portion of a conventional single-bevel hypodermic needle 600a, forcomparison purposes, and FIG. 6B shows perspective, isometric and cross-sectional views of a distal end portion of an example embodiment of a combined conical-and-bevel needle 600b having a conical outer profile as the primary penetrating geometry with a bevel face 602b cut into a cone 604b at the tip of the needle 600b. The conical outer profile has a half-angle between about 5 degrees and about 15 degrees. By removing wall thickness at the leading edge of the tip of the needle 600b, this design results in a shorter bevel opening length (for example, a reduction from 0.14 mm if the needle 600a is a conventional 30G needle with 45 deg bevel to 0.10 mm for the combined conical-and-bevel tip, approximately a 29% reduction), which is advantageous when penetrating through multiple thin tissue layers at a posterior location of the eye, where each layer (e.g., sclera, choroid, subretinal space) is only a few hundred micrometers thick, while also being sharper than the standard 45 degree bevel 602a.

[0132] By keeping the length of the bevel opening 606b below about 100 micrometers, the opening 606b can be configured to span only a single tissue layer or space at a time during penetration, which prevents drug leakage into adjacent tissue layers or spaces.

[0133] The needle 600b may be made from Nitinol, stainless steel (e.g., 304 or 316L grade), or other biocompatible materials. The surface of the needle 600b may include one or more coatings such as diamond-like carbon (DLC), parylene, or polytetrafluoroethylene (PTFE) to reduce friction during tissue penetration.

[0134] For some cases, it may be preferrable to have a needle tip geometry which is axially symmetric in order for the needle tip to stay centered when the needle is being extended and rotating following a screw motion rather than tracing an arc which occurs when a traditional beveled needle is turned about its axis. Referring now to FIG. 7A, shown therein is an example embodiment of a distal portion of an axially symmetric needle tip 701a with the point of the needle tip 704 coincident with a symmetric longitudinal axis 703 of the needle shaft of the needle 701 a. The tip of the needle 701a is closed and cone shaped (e.g., is a solid conical tip), and one or more holes / side ports 702 are placed at a distal end portion of the needle 701a, such as on a conical portion / face adjacent the needle tip 704, to dispense fluid, for example. The holes / side ports 702 connect to the main lumen (not shown) of the needle 701. The needle 701a may be more suitable for “drilling”-style advancement where symmetryabout the main axis 703 of the tip 704 is preferred and fluid is dispensed through the side ports rather than through an axial bevel opening. Alternatively, in other embodiments, such as the distal end portion of the needle 701b shown in FIG. 7B, the needle 701 b has a small hole 705 at the very tip that is connected to the main lumen (not shown). In some applications, the needle 701b may be used as a coring needle, in which case filling the needle 701b with fluid prevents a plug of tissue from entering into the hole 705.Preventing Tenting of the Choroid

[0135] A challenge with inserting a needle tip into the subretinal space is the deflection or “tenting” of the choroid and RPE around the needle tip as the needle tip pushes against the choroid and RPE during insertion / needle deployment. This is illustrated in FIG. 8 which shows a distal end portion of a needle 203 that has penetrated the sclera 104 but where the tip of the needle 203 has not punctured either of the choroid 102 or the retina 101.

[0136] Tenting occurs due to the elasticity of the tissue which does not provide enough resistance to needle insertion forces to prevent deflection and allow for the needle to penetrate through the tissue. Without a solid foundation under the soft object to resist the piercing force, the object will just move away from the sharp edge or tip. This tenting may happen before the needle tip punctures the tissue, as well as after the needle tip partially punctures the tissue but frictional forces between the needle tip and tissue prevent the tissue from sliding smoothly over the needle tip and end of the needle.

[0137] One method which may be employed to combat tenting is vibration of the needle tip, which has been shown in multiple studies to reduce peak needle insertion forces and help needle tips enter tissue with less deflection of the tissue surface [4], [5], [6], [7], An example embodiment of a schematic of a portion of a device is shown in FIG. 9, which has a needle holding member 300nh, which is supported by one or more elements so that it can be modeled as a bending beam in this example (as discussed in PCT patent application no. PCT / CA2025 / 050544), where axial vibration of the needle 203 can be induced by attaching a motor 901 to rotate an eccentrically mounted mass 902 or by placing a piezoelectric actuator adjacent to or mechanically coupled to the beam of the needle holding member 300nh. The motor 901 is coupledto the needle holding member 300nh at a location between the proximal support and the pivot 304 to impart vibrations to the needle holding member 300nh which result in semi-axial vibration of the tip of the needle 203 during penetration of the eye. The piezoelectric actuator or the rotating eccentric mass 902 provides a harmonic excitation force that may be aligned to be perpendicular with the longitudinal axis of the needle holding member 300nh in order to cause bending displacements in the direction of the needle’s penetration axis into the tissue. The varying angle of the distal end of the needle holding member 300nh as the needle holding member 300nh vibrates causes the needle 203 to move back and forth approximately axially (e.g., along the longitudinal axis of the needle 203). The location of the actuator (e.g. the motor 901 or the piezoelectric actuator) can be adjusted to tune the frequency and amplitude of the vibrations along the needle holding member 300nh. In the embodiment illustrated in FIG. 9, the motor 901 having the eccentric mass 902 is placed at the center of the needle holding member 300nh to be at the location of maximum amplitude for the first vibration mode. However, in other embodiments, the motor 901 and eccentric mass 902 or the piezoelectric actuator may be placed elsewhere along the beam based on the input frequency and amplitude of the excitation force and the desired output frequency and amplitude of the needle 203: In any particular device, there will be vibration mode shapes, and the motor or piezoelectric element may be positioned to maximize vibration excitation of the beam’s vibration amplitude. Fora simply supported beam with a cantilever extension holding the needle, the first vibration mode has maximum amplitude in the middle between the support points so attaching the vibrator at the middle of the support points will result in maximum amplitude of the cantilever tip with the needle.

[0138] A challenge with vibrating the needle 203 may be to control the vibration so that the needle 203 may puncture the choroid but does not puncture the retina. However, research shows that the choroid has a modulus of elasticity that is orders of magnitude higher than the retina, meaning it is much stiffer than the retina [8], Accordingly, in at least one embodiment, the modulus of elasticity of the choroid may be used to pick a vibrational frequency and amplitude which allows the needle 203 to puncture the choroid more easily, but not the retina. For example, the needle tip may oscillate at a small amplitude such that the needle tip punctures the choroid becausethe choroid is relatively stiffer than the retina; however, the needle tip will not puncture the retina because the retinal tissue is elastic enough to move with the needle tip.

[0139] In another embodiment, tenting of the choroid may be overcome by prestretching the choroid before puncturing it with a needle that creates higher local stress in the choroidal tissue. This may be done by using a two-stage needle, e.g., a doubleneedle configuration. Referring now to FIG. 10 shown therein is a magnified view of a distal end portion of a double needle assembly including a smaller nested needle 1001 inside a larger needle 203 where the larger needle is used to penetrate the sclera 104 pushing against the choroid 102 during needle insertion. Once the choroid 102 is draped over the larger needle 203, and essentially preloaded to prevent further deflection, the smaller needle 1001 can be axially advanced out of the distal opening of the larger needle 203 to puncture the choroid 102 and reach a deeper structure, such as the subretinal space. For example, a 34-gauge needle or cannula may be advanced through a 30-gauge needle or cannula. The nested needle (e.g., smaller diameter needle) may be straight or pre-curved.

[0140] In some cases, the end of the outer needle 203 may be retracted before the inner needle 1101 is used to penetrate the choroid. For example, FIG. 11 shows a magnified view of the distal end portion of the double needle configuration / assembly where the end of the outer needle 203 has been retracted such it doesn’t penetrate as deeply into the eye before the inner needle 1001 is extended. In this embodiment, the smaller nested inner needle 1001 is also pre-curved so that after puncturing the choroid 102 it advances tangentially within the subretinal space, forming a subretinal bleb 1101 between the retina 101 and the choroid 102 while remaining spaced apart from the point of choroidal penetration. It may be advantageous to have the nested needle pre-curved in this manner so that after an initial hole is made by the larger needle 203 in the outer surface and sclera 104 of the eye 100, and the larger needle 203 is retracted slightly, the smaller needle 1001 may then be further advanced tangentially to penetrate the choroid 102 without as much “tenting” and then extend into the sub-retinal surface in order to ensure or improve the likelihood that the entire needle bore opening is in the subretinal space before injection. During injection, a subretinal bleb 1101 is then formed between the retina 101 and the choroid 102 as shown (with cross-hatching for illustrative purposes) in FIG. 11. This will ensure or improve the likelihood that there is minimal reflux of drug, treatment fluid or othermaterial / objects into the suprachoroidal space since the needle opening is entirely or more fully contained in the subretinal space 103 and the injection location is farther away from the hole made by the small needle 1001 in the choroid 102 which may otherwise be a source of leakage. This can also decrease the risk of puncturing the retina 101. In order to maintain the pre-curved shape of the nested inner needle 1001, Nitinol, which has super-elastic properties as well as shape-memory properties, can be used to form the nested needle. Nitinol can allow the nested inner needle 1001 to be pre-shaped by heat treatment to a desired geometry, stored straight in the larger diameter outer needle 203, and then once deployed out of the larger needle regain its original shape once in the eye 100.

[0141] The nested inner needle 1001 can be controlled by a second control input such as a rotating wheel pair (e.g., rollers that pinch the inner needle 1001 between them, in which one or both rollers may be driven), a lever mechanism, or a leadscrew through which the needle passes and is affixed, an example embodiment of which are devices 1200a and 1200b of which portions are shown in sectional views of FIGS.12A-12B. The devices 1200a and 1200b include example embodiments of needle drive assemblies for actuating a two-stage needle assembly, having two needles. The control wheel 303, which may be referred to as a primary control element, primary control input, a primary control wheel in the various embodiments described herein, is used for actuating the pivoting needle holding member 301 about the pivot 304 to deploy the outer needle 203. A secondary drive is used to advance the inner needle 1001 through the outer needle 203.

[0142] The devices 1200a, 1200b include a rotating wheel pair 1202 including a secondary friction drive wheel 1203 that is coupled to an input wheel 1201 and a free-spinning backup wheel 1204 that is not coupled to the input wheel 1201 but may be pivotally connected to an inner portion of the housing of the device 1200a to freely rotate about a pivot point 1205 (such as a pivot pin). The input wheel 1201, which may be referred to as a secondary input wheel, a secondary control wheel or a secondary control element in the various embodiments described herein, is used to actuate the inner needle 1001. The wheels 1203 and 1204 are co-located with one being driven and the other being free spinning so that a proximal portion of the inner needle 1001 is pinched (held and driven) between the drive 1203 and backup wheels 1204. Thus, when the input wheel 1201 is turned, the small diameter inner needle 1001 isadvanced axially through the outer needle 203 without slipping between the wheels 1203 and 1204. Because the inner needle 1001 has to advance small distances, the proximal end of the inner needle 1001 is slidably moveable through a front seal 1206s of a fluid vial 1206 to allow for advancement while still allowing the upper end of the proximal end portion of inner needle 1001 to be located within the vial 1206 and be fluidically coupled to the vial 1206.

[0143] Alternatively, in some embodiments, such as for device 1200b shown in FIG. 12B, a flexural section 1207 of the proximal end of the inner needle 1001 permits the proximal end of the inner needle 1001 to remain fixed in place in / at the vial 1206 in order to interface with the vial 1206 for various purposes, such as receiving treatment fluid, while the distal end of the inner needle 1001 translates through the outer needle 203 and the whole needle assembly (e.g. distal portions of the inner needle 1001 and outer needle 203) pivots as the distal member 306 of the outer needle holding member 300nh pivots about pivot 304. The flexural section 1207 can bend elastically as the needle holding member 300nh is moved. The proximal regions / portions of the outer and inner needles are generally indicated by 203p and 1001 p, respectively. The low stiffness of the small diameter inner needle 1001 , relative to the stiffness of the outer needle 203, allows the inner needle 1001 to turn inside the right-angle bend of the distal portion of the outer needle 203 and for the inner needle 1001 to bend and slide to accommodate the proximal end movement that occurs when advancing the outer needle 203, which is controlled by movement of the input wheel 303 that is coupled to the upper portion of the proximal member 301. The sizing of the friction drive and free spinning wheel 1203 and 1204, relative to the size of the input wheel 1201, can be tuned to change the amount the nested inner needle 1001 advances for each rotation of the input wheel 1201. Accordingly, in the devices 1200a and 1200b, one input control (e.g., input wheel 303) can be used to extend / retract the distal portion of the outer needle 203 while another input control (e.g., input wheel 1201) can be used to extend the distal portion of the inner needle 1001 relative to the outer needle 203.

[0144] Alternatively, the nested needle axial position may be controlled by a lead screw and nut system, also referred to as a lead screw and nut assembly, where the input wheel 1201 interfaces with a screw or a nut to create axial motion. FIG. 13 is a sectional view of a portion of an example embodiment of a device 1300 having a right-angle gear pair with a drive gear 1301 that is integral with or attached to the input wheel 1201 that rotatably engages a driven gear 1303 with a nut at its center, and the nut mates with a leadscrew 1302. The position of the driver gear 1303 is fixed in place. As the input wheel 1201 turns, the drive gear 1301 also turns which causes the driven gear 1303 to rotate in place about an orthogonal axis via the right-angle gear pair, forcing the leadscrew 1302, which is constrained to not rotate, to move axially and thereby advance the inner needle 1001 through the outer needle 203. Accordingly, this drive assembly converts rotation of the input wheel 1201 about one axis into axial motion of the inner needle 1001 through the outer needle 203. The lead of the leadscrew 1302 and the gear ratio between the interacting gears 1301 and 1303 can be tuned to adjust the amount the nested inner needle 1001 advances for each rotation of the input wheel 1201. Otherwise, the device 1300 operates in a similar fashion as device 1200a.

[0145] The axial motion of the inner needle 1001 may, in another embodiment, be driven by a rack and pinion, where the pinion gear is mounted in the center of the input wheel 1201 and a following rack, which is attached to the small inner needle 1001, is axially advanced due to gear teeth interaction between the rack and pinion when the input wheel 1201 is turned.

[0146] In other embodiments, the nested inner needle 1001 may be driven such that the inner needle 1001 twists / rotates in a drilling motion as it advances or retracts which reduces friction and needle insertion forces that are used to puncture the choroid 102 without deflecting the choroid 102 (e.g., without tenting). Furthermore, by rotating the inner needle 1001 while advancing the inner needle 1001 , the inner needle 1001 will translate much more easily through a curved outer needle at the tip of the distal end portion of the device.

[0147] In one embodiment, the follower gear 1303 and leadscrew 1302 are rigidly connected (or made integral) and the leadscrew 1302 is supported by a fixed nut. Hence when the leadscrew 1302 is turned, the leadscrew advances and also rotates the inner needle 1001 simultaneously. This helps to reduce buckling of the inner needle 1001 as a rotating needle is more likely to screw itself forward. Note in the drawing shown, while the thin / smaller diameter inner needle 1001 is not shown in a tubular housing, in some cases it may be preferable to house a distal portion of the thin inner needle 1001 , spaced apart back from the tip of the inner needle 1001 , in ahousing or sleeve as this will help prevent the thin inner needle 1001 from merely buckling rather than being forced forward. The housing may be a simple flexible tube with a slightly larger inner diameter compared to the outer diameter of the inner needle 1001.

[0148] Referring now to FIG. 14, shown therein is a sectional view of a portion of an example embodiment of device 1400. A nested inner needle advancement actuation (e.g., needle drive assembly) is used in the device 1400 to both advance and turn, like a screw, which here is accomplished by using a back-up roller 1402 that rotates on an axle attached to the device body / housing and a friction drive wheel 1403 coupled to the input wheel 1201 to axially push a body 1401 pinched between the two wheels 1402 and 1403 which is coupled to a back-drivable screw body 1405 without rotationally constraining it. The back-drivable screw body 1405 has on its outer cylindrical surface a helical thread or cam slot that engages a stationary nut or cam 1404 such that axial motion back-drives the screw body to also rotate. The nested inner needle 1001 is attached to the back-drivable screw body 1405 so the inner needle 1001 will exhibit axial and twisting motion simultaneously when actuated by the screw or cam. Accordingly, the needle drive assembly of the device 1400 is configured to produce simultaneous axial and rotational (“screw”) motion of the nested inner needle 1001 as it advances.

[0149] Referring now to FIG. 15, shown therein is a sectional view of a portion of an alternative embodiment of a device 1500 that uses right-angle helical gears 1502 and 1504 to produce the same simultaneous axial and rotational motion of the inner needle 1001. The helical gear 1502 is a helical gear tooth wheel gear that is attached to or integral with the input wheel 1201 and engages a helical gear 1504 which is a driven gear that is coupled to a back-drivable screw 1506 and nut 1503, with the inner needle 1001 being coupled to the combined driven gear 1504 and screw body 1506 such that rotation of the input wheel 1201 drives the inner needle 1001 both axially and rotationally. A limit member 1505 axially constrains the driven gear 1504 and the vertical upwards movement of the upper end of the driven gear 1504. The inner needle 1001 also includes a flexural section 1207 whose purpose was described earlier.

[0150] An advantage, in addition to reducing tenting of the choroid 102, of using a needle drive assembly that provides rotation with translation for the inner needle 1001 movement is that the tip of the inner needle 1001 can be at an angle to the normal tothe surface of the eye 100 so that the sharp tip of the inner needle1001 more easily penetrates through the tough sclera 104 of the eye 100. As the inner needle 1001 penetrates the sclera, the bevel at the needle tip rotates to be oriented more towards the center of the eye 100 as it penetrates the choroid 102 for subretinal injection of treatment fluid for retinal disease. This reduces the chance for the sharp tip of the needle 1001 to tent and penetrate through the choroid 102 and thus reduces the risk of unintentionally penetrating the retina 101. Even though the contact surface curved distal end portion of the device, through which the inner needle 1001 is guided and extended through, may intersect the sclera 104 at an angle of about 45 degrees, the needle bevel tip can be oriented near parallel to the normal to the sclera 104 and hence the needle tip will penetrate most easily as it pushes and rotates into the sclera 104.

[0151] In one example embodiment, using the needle drive mechanisms I needle drive assemblies of devices 1400 or 1500 shown in FIGS. 14 or 15, given certain dimension for the various parts of the needle drive assembly, after about 4.5 rotations of the input wheel 1201, the inner needle 1001 has advanced about 2 mm and the needle bevel at the needle tip of the inner needle 1001 is close to being tangent with the outer surface of the choroid 102 so that the needle tip is less likely to penetrate and cause damage to the retina after the needle penetrates through the choroid. This is also an advantageous orientation such that fluid exiting the lumen of the inner needle 1001 is directed at the retina. For advancing the inner needle 1001 through the sclera 104 to just near the choroid 102 and then to create a subchoroidal bleb to buckle the choroid 102 outward, the rotation amount may be at increments of 0.5, 1.5, 2.5, or 3.5 rotations of the input wheel 1201 to bring the needle bevel from facing away from the sclera 104 to facing towards the inside of the choroid 102, for example, rotating the needle bevel 180 degrees. For finer axial motion control, a finer screw pitch can be used. As a rule of thumb, to obtain high fidelity of axial position and rotation control, the screw pitch may be from 0.1 mm to 0.5 mm.

[0152] In some embodiments, if a laser light is shone through the bore of the inner needle 1001, the brightness of the light from the bore of the inner needle 1001 may be used to assess if the bevel is fully in the subretinal space 103.

[0153] In some embodiments, if the tip of the inner needle 1001 is not inserted deep enough into the eye 100, but the user of the device wants to then advance the needletip a small amount without rotating the needle tip, then the needle drive mechanism / assembly may include a forward support block mounted in a slider or flexural support that only allows for forward motion, such that when the drive spindle is pushing the inner needle 1001 forward, the support block does not move. However, at this point, the user may apply a forward force to the drive spindle without rotating it to push the slider forward to advance the needle tip further into the eye 100 by one or more fractions (e.g., about one or more tenths) of a mm.

[0154] In yet another alternative embodiment of a needle drive assembly, the user can easily index the drive spindle directly. In such an embodiment, the gear teeth on the drive spindle, which is a type of gear that is used to extend / retract a needle, such as screw 1506, screw body 1405, for example. In such cases, the drive spindle are not used as a gear per se, but rather as a tactile device that the user can push with their finger, where 45-degree teeth can be used to indicate to the user to move their finger axially and tangentially so as to slide along the tooth of the drive spindle as the wheel is rotated. This enables the user to directly push forward on the helical gear tooth, with their finger sliding along the tooth, such that the user can easily index the drive spindle by a certain amount. As an example, with a screw pitch of 0.45 mm and 16 teeth on the gear, one index forward of the user’s finger on a gear tooth gives an axial resolution of about 30 microns. This greatly simplifies the device and reduces manufacturing cost. The helical gear teeth may have a diameter of about 18 mm so that a user’s index finger can comfortably push on each tooth in sequence. In an alternative embodiment, fully rounded teeth may be used to provide a softer feel to the user’s finger yet still retain the 45-degree indexing effect.

[0155] Referring now to FIG. 16, shown therein is a sectional view of a portion of an example embodiment of a device 1500 that has an electronically controlled needle drive mechanism / assembly for the inner needle 1001. The drive assembly includes a motor / gearbox 1601 which drives an output gear 1602 that is coupled to a driven gear 1603 having a coupled screw body 1605 that passes through a stationary support block 1606 with a threaded channel 1606, such that rotation of the motor / gearbox 1601 causes the driven gear 1603 and the coupled screw body 1605 to translate axially while simultaneously rotating, thereby advancing and rotating the inner needle 1001 as it moved through the outer needle 203. The inner needle 1001 is axially coupled to the screw body 1605 such that the inner needle 1001 moves axially and rotates whenthe coupled screw body 1605 moves linearly and rotates. A proximal end of the inner needle 1001 is also fluidically coupled to the vial 1206. In this example embodiment, the upper end of the proximal portion of the inner needle 1001 has a flexural section 1207 such that the proximal tip of the inner needle can be at a fixed location and the flexural section 1207 can be straightened / stretched as the tip of the inner needle 1001 is deployed / extended by the needle drive assembly and bends as the tip of the inner needle 1001 is retracted by the needle drive assembly.

[0156] In some example embodiments, the drive spindle (e.g., the driven gear 1603) may have an involute spline portion driven by a simple involute gear pinion attached to the output shaft of the motor / gearbox 1601, such that the screw thread portion and the spline portion together form a “spline screw.” As the pinion (output gear 1602) rotates, it causes the spline screw to rotate and advance, giving the user fine motor control for needle advancement and retraction, and also enabling the device to be wielded by a surgical robot for even greater fidelity.

[0157] In other embodiments where the inner needle advancement is controlled by a motor, a nut can be located at the center of the driven gear and the lead screw can be rotationally constrained such that the inner needle only advances axially without rotation.

[0158] In one or more embodiments, the device assembly may further include a motor which is used to control motion of a plunger in the vial to dispense fluid or to remove a substance from the target.

[0159] The device assembly also includes a controller for the motors as well as an input device (e.g., a control foot pedal with two input buttons or pads) which is used by the user to control the actuation of the inner needle 1001 and / or the plunger of the vial.

[0160] Referring now to FIG. 17, shown therein is a sectional view of a portion of another example embodiment of a device 1700 having a manually actuated needle drive mechanism / assembly that uses a crankshaft arrangement to translate proximal motion of the input wheel 1201 into advancement of the distal end portion of the inner needle 1001. The crankshaft arrangement includes a crank arm 1701 with a proximal end coupled to the input wheel 1201, a linear bushing 1703 that is coupled to a distal end of the crank arm 1701 and a track 1702 that is integral with or connected to the pivoting beam 301 of the needle holder member in which the linear bushing 1703moves linearly. Rotation of the input wheel 1201 drives the proximal portion of the crank arm 1701 whose free end is coupled by a connecting link to the linear bushing 1703 that is constrained to translate along the pivoting beam 301. The linear bushing 1703 is also fixed to a proximal end portion of the inner needle 1001 (or a holder thereof), such that rotation of the input wheel 1201 advances the inner needle 1001 through the outer needle 203 by a predetermined stroke determined by the crankshaft geometry. The crankshaft geometry (e.g., crank radius and connecting link length) may be selected to provide a desired relationship between input wheel angular displacement and inner needle axial advancement, and to provide additional mechanical advantage at end-of-stroke where tissue penetration forces are typically largest. The motion of the outer needle 203 is still controlled by the input wheel 303.

[0161] Test were simulated for the device 1500 using a drive spindle with certain screw thread parameter vales shown in Table 1 and helical gears with different parameter values shown in Table 1 where the different test cases for the helical gear are shown in the columns of Table 1. Table 1 shows example helical thread pitch calculations, indicating the high efficiency of the needle drive system. For example, one figure of merit is the efficiency and amount of rotation. It is preferable to have high efficiency so that minimal effort is needed for actuation, but there is also significant rotation to provide a large mechanical advantage for less finger force and greater motion resolution.TABLE 1Axial motion screwthreadThread flank angle (deg) 10Pitch (mm) 0.45Pitch diameter 2.25Beta 0.2Stroke (mm) 2Rotations 4.44Helical gearGear helix pitch, (mm) 18.85 14.14 9.42 Gear pitch diameter, dscrew (mm) 6 4.5 3 helix angle (radians) 0.785 0.785 0.785 (degrees) 45.0 45.0 45.0 Beta 3.142 3.142 3.142 Coefficient of friction 0.10 0.10 0.10Efficiency to transmit torque into force 38% 38% 38%

[0162] T able 2 shows how needle gauge affects bending stress as the inner needle 1001 is forced through a curve. Importantly it also shows the bending stress is beyond yield which means as the inner needle 1001 exits the curved distal end portion of the device, the inner needle 1001 will want to remain curved which helps prevent the needle from deflecting off course as it follows the needle path on its way to the target location / region / area. Also, the axial force needed to push the inner needle 1001 is estimated by assuming two points support the moment created by bending the needle. The lower the force is the better it is for ergonomics. The force to axially advance the inner needle 1001 through the tissue must also be less than the buckling force of the inner needle 1001. However, in devices that employ a sleeve or tube for the inner needle 1001 , if the inner needle 1001 buckles, it can still slide along the sleeve.TABLE 2

[0163] In one or more embodiments, during manufacture, a Teflon sleeve may be placed over the inner needle and then the sleeve is placed in a larger guide bore as a liner, where the larger guide bore may be the lumen of an outer needle. This liner may be constrained to not move as the inner needle advances through it. This may also facilitate making the bore larger which is easier to mold. A Teflon sleeve can also be made to tighter tolerances and will provide lowest friction as the needle moves within it.Alternative Slow-Release Drug Delivery Mechanisms

[0164] In some situations, it may be advantageous to attach or insert an implant in the eye which allows for controlled release of drugs to the subretinal or suprachoroidal spaces overtime.

[0165] Several devices described in U.S. patent application publication no. US-2025-0064635-A1 and in the subject use a motor, gearbox, and leadscrew system to allow a user to more easily inject viscous material into the eye with those devices.Viscoelastic infused with drugs which are absorbed as the material dissipates on the timescale of months may be delivered with such devices directly to the subretinal space without the need for a vitrectomy.

[0166] Microneedle patches are another popular route of slow-release drug administration. FIG. 18 depicts an example embodiment of a device 1800 that can deploy a microneedle patch 1801. The device 1800 is positioned against the exterior surface of an eye at the posterior of the globe, with the distal end portion 202d in contact with the sclera 104. The device 1800 may have similar actuation components / drive assemblies as one of the side-firing devices described herein or in U.S. patent application publication no. US-2025-0064635-A1 and PCT patent application no. PCT / CA2025 / 050544PCT. However, the distal end of a needle holding member 1800nh is modified to store the microneedle patch 1801 or other externally placed device which is then deployed from a lateral surface of the device end portion 202 of the device 1800 and pushed onto a proximal portion of the sclera 104 by actuation of the needle holding member 1800nh. The microneedles used in the microneedle patch 1801 are preferably long enough to pass through the sclera 104 and embed into the suprachoroidal or subretinal space. For devices that can deploy a microneedle patch 1801, the distal end portion of the device is modified to have a larger aperture through which the microneedle patch 1801 is deployed. A weak adhesive may be used to attach the microneedle patch 1801 onto the distal end of the needle holding member 1801 such that the adhesive forces are overcome once the needles of the microneedle patch 1801 are embedded into the eye 100 and the distal end of the needle holding member 301 a is moved away from the eye 100. It should be noted that in other embodiments the device may be used to deploy a stent or a port with the end portion of the pivoting beam 301a being adapted to hold the stent or port and then release the stent or port when it is at the desired location during use.Conjunctiva Cutting Mechanisms

[0167] When reaching further back in the eye, the conjunctiva 108, a mucous membrane that covers the front of the eye 100 and folds over and connects to the eyelids, may inhibit any of the devices described above from reaching the very posterior parts of the eye 100 including the macula 110. However, a small cut can be made in the conjunctiva 108 to permit advancement of the entire device distal endportion to the posterior regions of the eye 100. This is a minor operation which can be performed with surgical scissors. However, in some embodiments of the device it may be convenient for the device itself to have a sharp feature at the tip of the distal end portion which can be used to create the hole in the conjunctiva 108 without having to use a separate instrument to make this small cut, to streamline the surgical workflow and reduce instrumentation requirements.

[0168] In accordance with the teachings herein, the tip of such a device may be sharp, and may be shaped like a trocar. The trocar can be referred to as an end effector that is used for conjunctiva management. The sharp tip can be integrated into the design of the device body and injection molded so that no extra parts are required. In other embodiments the tip can be a separate part that is attached to the device body. Three example trocar tip embodiments are shown in FIGS. 19A-19C. FIG. 19A shows three views of a pyramidal trocar 1901 with 3 sides that meet at a point. FIG.19B shows three views of a conical trocar 1902. FIG. 19C shows three views of a conical trocar 1903 with one side cut to create a flat face. The advantage of a plastic trocar is that it may not be sharp enough to cut tissue through simple contact like a blade would, although in some embodiments, trocars of metal or other materials could also be used. Trocars rely on significant axial force of the device tip pushing tangent to the eye 100 to stretch the conjunctiva 108 then cause it to tear. The trocar is at the distal end surface of the device, whereas the needle exits the side (lateral surface) of the distal end portion of the device. With this configuration, the user can cut the conjunctiva while holding the device in the usual orientation with the needle exit location facing the eye and pushing the device towards the desired posterior position on the eye. Once in place, the lateral contact surface of the device can be used to indent the eye and the trocar is not in contact with any tissue of the eye and is out of the way. This allows the device thickness to remain small. In some example embodiments, the length of the trocar can range from approximately 1 to 10 mm of additional length on the tip of the device, with shorter lengths preferred in order to not make contact with other non-target tissues in the posterior globe.

[0169] Alternatively, referring to FIG. 20A, shown therein is an example embodiment of a device 2000 that has a sharp blade 2001 that may be extendable from the tip 2000t of the device 2000. The blade 2001 is referred to as an end effector that may be used conjunctiva management (e.g., making a small hole in the conjunctiva). Sincethe distal end portion of the device 2000 will be behind the eye and in contact with or near the eyelids, sclera 104, ocular muscles, optic nerve 106, and other structures, it is important that the blade 2001 does not accidentally cut unintended tissue. Thus, the blade 2001 may be moveable such that it can be extended or retracted using an actuator such as a slider 2002, button, or other input mechanism by the user that is mechanically coupled to the blade 2001 so that movement of the input mechanism causes movement of the blade 2001. In the pictured embodiment in FIG. 20A, the blade 2001 is oriented so that the flat plane of the blade 2001 is tangent with the eye, making cutting of the sclera or eyelid less likely. This may be achieved by having the blade 2001 exit near an opposing surface OS of the device rather than the lateral surface LS.

[0170] In at least one embodiment, the blade 2001 may be pointed and tapered as shown in FIG. 20B. This allows the user to make a very small hole that can then be stretched and opened by the distal end portion of the device 202. In some embodiments, the blade 2001 may be designed in such a way that it is only sharp at a distal tip 2003 of the blade 2000 and is dull at a proximal edge 2004 to reduce the size of the hole created by the sharp tip 2003 since the conjunctiva is a very elastic tissue and the distal end portion of the device 202 may be able to be pushed through a small hole. In other embodiments, the blade 2001 may be rectangular or curved to make a more linear incision.

[0171] It may be inconvenient for the user to have to use a separate control input to extend and retract the blade 2001 from the tip of the device 2000. Instead, referring to FIG. 21 A, there is shown a portion of an example embodiment of a device 2100 having a spring-loaded cover 2101 for the blade 2001 that is located at the distal tip of the device 2100 such that when the tip of the device 2100 is pressed adequately hard using a force F against the conjunctiva 108, the cover 2101 is deflected to expose the tip of the blade 2001 just enough to cut the tissue in front of the tip of the blade 2001. FIG. 21 A shows a non-deflected cover 2101, and FIG. 21 B shows the cover 2101 deflected. The cover 2101 has a first end that is coupled to a portion of the device tip of the device 2100 and is flexible, as well as a second end that is free-moving. With this structure, when a force is applied to a midportion of the cover 2101 or the free-moving end of the cover 2101 , the tip of the blade 2001 is exposed and can be used to make an incision, which may be done as described previously. As soon as theincision is made and the device distal end portion 202 slides past the conjunctiva, there will no longer be force directed axially along the device tip 21 OOt of the device 2100 and the cover 2101 will spring back into place to conceal the blade 2001 and prevent accidental cutting of any unintended tissue. In at least one embodiment, such as the embodiment pictured in FIG. 21, the spring-loaded cover 2101 is a flexural element built into the outer body 302 of the device 2100 so that no extra parts are necessary. The force required to deflect the spring-loaded cover 2101 to expose the blade 2001 can be tuned by changing the thickness, length, or width of the end of the spring-loaded cover 2101 that is attached to the outer body 302 since all of these variables are related to the stiffness and bending of the spring-loaded cover 2101. In other embodiments, a coil spring may be used to maintain the position of a separate cover body.

[0172] In an alternative embodiment of these devices with a cutting blade, the distal tip of the device may apply a suction force to pull / pick up a small amount of conjunctiva and then the blade 2000 or guillotine-like mechanism within the device may be used to cut the conjunctiva.Expandable Trocar

[0173] In another aspect, in some embodiments, a device is provided which includes an expandable trocar for creating and maintaining an opening through the conjunctiva. The trocar is another example of an end effector that may be used for conjunctiva management. Referring now to FIG. 22A, an expandable trocar 2201 is shown which is a separate component that includes a flexible expandable portion 2202 made from a biocompatible material and functioning similarly to an expandable vascular stent. FIG. 22A shows the expandable conjunctival trocar 2201 in a collapsed configuration for insertion through the conjunctiva 108. The expandable trocar 2201 has a distal end portion 2204 with a sharp distal tip 2203 sized and shaped to puncture the conjunctiva 108, creating a small initial hole. The trocar 2201 has a quasi-conical / cylindrical shape with walls defining an inner lumen 2205. In use, the expandable trocar 2201 is first inserted through the conjunctiva 108 in a collapsed configuration as shown in FIG. 22A, creating a small initial hole in the conjunctival tissue 108. The collapsed profile of the trocar 2201 is small enough that the initial puncture is comparable in size to the holes created by the trocar tips or blades described above.

[0174] Referring now to FIG. 22B, shown therein is the expandable trocar 2201 in an expanded configuration with the device distal end portion 202 inserted through the bottom end trocar 2201 which was once the sharp tip 2203. Once the distal portion 2204 of the expandable trocar 2201 is in place through the conjunctiva 108, the device distal end portion 202d is advanced through the lumen 2205 of the trocar 2201 (device 300 is being shown herein for illustrative purposes but other devices described herein (without the cutting blade) may be used). The flexible portion 2202 of the trocar 2201 is expanded around the device 300 to hold the conjunctiva 108 open because the device distal end portion 202d has a larger cross-sectional profile than the collapsed trocar 2201 , the flexible portion 2202 of the trocar 2201 expands radially as the distal end of the device 300 passes through it, stretching the surrounding conjunctival tissue to accommodate the device 300. The trocar 2201 remains stationary relative to the conjunctiva 108 while the device 300 passes through it, with the expanded flexible portion 2202 acting as a protective sleeve that distributes the stretching force over a larger area of conjunctival tissue and prevents tearing or uncontrolled extension of the initial hole.

[0175] Because the conjunctiva 108 is an elastic tissue, this controlled stretching allows the device distal end portion 202d to pass through without requiring a large initial incision. The expanded flexible portion 2202 of the trocar 2201 holds the conjunctival tissue 108 in an open, stretched configuration for the duration of the procedure, so that the device 300 can be advanced, repositioned, or withdrawn through the conjunctival opening without the conjunctiva collapsing around or dragging against the device body. Upon completion of the procedure, the device 300 is withdrawn from the trocar 2201 , and the trocar 2201 may then be removed. Once the trocar 2201 is removed, the elastic conjunctival tissue recoils and returns substantially to its original configuration, resulting in a smaller residual wound and faster healing compared to a direct incision sized for the full device cross-section.

[0176] The flexible portion 2202 of the expandable trocar 2201 may be made from a shape-memory alloy such as nitinol, a flexible biocompatible polymer such as silicone or a thermoplastic elastomer, or a braided or laser-cut mesh structure. Nitinol is particularly advantageous because it exhibits superelastic behavior, allowing the flexible portion 2202 to undergo large radial deformations during expansion and reliably return to the collapsed configuration upon removal of the device, facilitatingeasy removal from the conjunctiva 108. The trocar 2201 may also be coated with a lubricious material such as PTFE or a hydrophilic coating to reduce friction during insertion of the device through the trocar lumen.A suction end effector

[0177] In the various deice embodiments described herein, the end effector of the device may also include a suction element for lifting a portion of the conjunctiva and a cutting element for incising the lifted conjunctiva.Diathermy

[0178] In at least some of the device embodiments described herein, it may be of further benefit to include a diathermy capability which can be activated when the needle is crossing one or more tissue layers, for providing hemostasis at or near the needle entry site and / or to modify the local tissue properties to allow for easier penetration of the needle. Diathermy is a well-established technique in ophthalmic surgery in which high-frequency alternating electrical current is passed through tissue to produce localized resistive heating for the purpose of coagulating blood vessels and achieving hemostasis. Diathermy is routinely used during vitreoretinal procedures to cauterize episcleral and choroidal blood vessels before or after scleral incisions to reduce intraoperative bleeding.

[0179] Diathermy instruments are generally classified as either monopolar or bipolar. In monopolar diathermy, a single active electrode is placed at the surgical site and current travels from the active electrode through the patient’s body to a dispersive return electrode pad attached to the skin at a remote location, such as the thigh or back. Because the current must traverse a large volume of tissue between the active electrode and the distant return electrode pad, monopolar diathermy produces a relatively broad and poorly controlled zone of thermal effect. This makes monopolar diathermy possibly less desirable for use in the posterior segment of the eye, where the retina, optic nerve, and choroidal vasculature are in close proximity to the surgical site and are highly susceptible to thermal injury. However, monopolar diathermy may still be useful in certain configurations, such as fine needle diathermy (FND) in which a single needle electrode delivers energy with a remote return pad.

[0180] Fine needle diathermy is an established ophthalmic technique in which a fine stainless-steel needle, such as a 3 / 8 circle needle attached to a suture or a 25-gauge needle, is inserted into or alongside a target blood vessel under an operating microscope. A monopolar diathermy unit set to a low coagulating mode is then brought into contact with the needle, and a return electrode is placed on the patient’s body such as strapped around the foot. Current is applied until blanching of the surrounding tissue is observed, typically for one second or less. The current flowing through the needle produces localized resistive heating at the needle tip that coagulates and occludes the target blood vessel. Fine needle diathermy has been used clinically for occlusion of corneal blood vessels and has demonstrated efficacy in treating corneal neovascularization. The technique is simple, inexpensive, and can be performed under topical anesthesia. The needle architecture of the devices described herein is analogous to a fine needle diathermy probe and may single needle embodiments may be used in a similar manner, whereas for devices herein with a smaller diameter inner needle disposed within a larger diameter outer needle either of these needles may serve as the monopolar electrode for delivering coagulating current to choroidal or scleral vessels at the needle entry site.

[0181] In bipolar diathermy, both the active and return electrodes are located at the surgical site, typically as the two tines of a bipolar forceps, and current flows only through the small volume of tissue captured / located between the two electrodes. Because the current path is short and confined, bipolar diathermy produces precise, localized heating with minimal spread to adjacent structures. For this reason, bipolar diathermy is possibly preferred in posterior segment ophthalmic surgery, such as for preventing bleeding of the choroid during subretinal injections. The devices described herein that may use a two-stage needle architecture is inherently well-suited for bipolar diathermy, as the concentric inner and outer needles provide two electrically distinct conductors already positioned at the target site.

[0182] Conventionally, diathermy is applied using a dedicated instrument that is separate from the injection or access device, requiring the surgeon to exchange instruments during the procedure. This adds operative time and requires the surgeon to reposition the access device after cauterization. Fora needle-based device it would be difficult to cauterize using the needle of a cauterizing device and then remove the device and insert a separate needle of a treatment device into the same area for treatment. Advantageously, the inventors have developed an integrated device that can deliver diathermy energy through the same needle assembly used for trans-scleralaccess, eliminating the instrument exchange and allowing hemostasis to be achieved without removing the device from the operative field.

[0183] Referring now to FIG. 23, shown therein is an example embodiment of a device with a two-stage (e.g., nested) needle assembly that is in a bipolar diathermy configuration. Exposed conductive portions of the outer needle 203 and the inner needle 1001 of the device serve as the two electrodes of a bipolar electrode pair for delivering high-frequency electrical energy to tissue between the two needles 203, and 1001. An insulating sleeve 2301, which may be the Teflon sleeve described herein or another biocompatible dielectric sleeve which may be made from polyimide or parylene, is disposed between the inner needle 1001 and the outer needle 203 so that the two needles are electrically isolated from one another along their length. In some embodiments, chemical vapor deposition may be used to apply a very thin (hundreds of nanometers to microns thick) layer of electrically insulating coating to the inner bore of the outer needle 203. An energy source such as voltage generator 2300, which may be an electrosurgical generator, is used to supply a high-frequency alternating current between the two needles 203, 1001, which causes current to flow from one needle through the intervening tissue to the other needle, producing localized resistive heating sufficient for coagulation of small blood vessels. For example, a positive voltage can be applied to the inner needle 1001 and a negative voltage or ground can be applied to the outer needle 203. Because both needles 203, 1001 act as electrodes and are co-located at the surgical site, the path for current flow is confined to the tissue immediately in front of and between the inner and outer needles 1001 , 203, minimizing collateral thermal damage to structures that surround the outer needle 203. In at least some embodiments, for greater precision in delivering diathermy, the distal end portions of the two needles 203, 1001 may be exposed (e.g., uninsulated) and conductive while more proximal portions are insulated so that only the tissue between exposed conductive end portions of the needles 203, 1001 receive diathermy. The electrosurgical generator 2300 may be coupled to the needles 203, 1001 via insulated conductors / leads 2300a, 2300b that run through the device housing and connect to the proximal ends of the outer needle 203 and the inner needle 1001 , respectively.

[0184] The two-stage needle architecture is particularly well-suited for bipolar diathermy because the concentric arrangement of the inner and outer needles 1001 , 203 inherently provides two electrically distinct conductors at the same surgical site,and the insulating sleeve 2301 serves as electrical isolation. This eliminates the need for a dedicated bipolar forceps or a separate cautery instrument, allowing the user to perform hemostasis and needle deployment with a single device.

[0185] A significant advantage of integrating diathermy into the needle assembly is the ability to apply thermal energy directly to the choroid from within the tissue, rather than only to the outer scleral surface as would be the case with a conventional diathermy instrument applied externally. When a conventional diathermy instrument is applied to the outside of the eye, the thermal energy must conduct through the full thickness of the sclera before reaching the choroidal vasculature, resulting in less precise control of which tissue receives heat and therefore potential thermal damage to the scleral tissue. By contrast, because the needle electrodes of the two-stage needle device are positioned at or within the choroid before diathermy is applied, the diathermy energy is delivered precisely where hemostasis is needed, with minimal thermal spread to surrounding structures. This localized choroidal application allows for more effective coagulation of the choroidal vasculature at the needle entry site while preserving the integrity of the overlying sclera.

[0186] Additionally, application of diathermy energy to the choroid and RPE may alter the mechanical properties of the tissue, making it easier for the needle to advance through these elastic layers. These elastic layers can otherwise present significant resistance to needle passage. The localized thermal effect of diathermy may cause a reduction in elasticity of the treated tissue ahead of or around the needle path, facilitating smoother passage of the needle through the choroidal and RPE layers and reducing the force required for needle advancement. In some embodiments, the user may apply a brief pulse of diathermy energy before or during needle advancement through the choroid and RPE layers to precondition the tissue and ease passage.

[0187] Referring again to FIG. 23, the diathermy function may be controlled by a controller 2302 and activated by a dedicated control input such as a foot pedal, a slider, a button or another user input device, such that the user can selectively apply diathermy energy before, during, or after needle insertion and penetration through one or more tissue layers without removing the device from the operative field. The controller 2302 typically has a processor and memory that stores program instructions, which when executed by the processor cause the controller 2302 to send a control signal to the voltage generator for generating a current having a desired amplitude,time duration and / or frequency to implement diathermy at the portions of the needles 203, 1001 that are exposed to the tissue between them. In some embodiments, the controller 2302 may be configured to limit the power, duration, or duty cycle of the diathermy energy to prevent excessive thermal damage. In some embodiments, the device may include a temperature sensor such as a thermocouple or thermistor at or near the distal end of one or both of the inner and outer needles 1001 , 203 to measure thermal data that may then be used as feedback for closed-loop power regulation. The controller 2302 may also include a visual or audible indicator to alert the user when diathermy is active. In some embodiments, the measured thermal data may be displayed to the user to provide visual feedback during diathermy.

[0188] In other embodiments, the device may be configured for monopolar diathermy rather than bipolar diathermy. In a monopolar configuration, one of the needles, either the inner needle 1001 or the outer needle 203, serves as the active electrode at the surgical site, and a dispersive return electrode pad is placed on the patient’s body ata remote location, such as strapped around the patient’s foot. Current flows from the active needle electrode through the intervening tissue to the remote return pad. In embodiments of the device having only a single needle rather than the two-stage nested needle configuration, the single needle may serve as the active monopolar electrode. Monopolar diathermy may be advantageous in certain clinical scenarios where fine needle diathermy techniques are appropriate, or where the simplicity of a single-electrode configuration is preferred.

[0189] In some embodiments, when the device has a two-needle architecture, the device may be switchable between monopolar and bipolar modes, allowing the user to select the appropriate mode based on the clinical situation.

[0190] While diathermy using high-frequency electrical current is one method of delivering energy through the needle assembly, in other embodiments the needle or needles may be used to deliver other forms of energy to tissue at or near the surgical site. For example, radiofrequency (RF) energy at frequencies and power levels different from those used in conventional diathermy may be delivered through one or both needles to achieve tissue ablation, coagulation, or modification.

[0191] In other embodiments, a laser fiber or waveguide may be routed through the lumen of the inner needle 1001 to deliver laser energy, such as from a diode laser, an Nd:YAG laser, or another ophthalmic laser source, to the target tissue at the needletip. Laser energy may be used for photocoagulation of choroidal vessels, for tissue cutting, orfor photodynamic activation of therapeutic agents delivered to the subretinal space.

[0192] In still other embodiments, ultrasonic energy may be delivered through the needle assembly. A piezoelectric transducer coupled to the proximal end of the needle may generate ultrasonic vibrations that propagate along the needle to the distal tip, where the mechanical energy can be used to facilitate tissue penetration, to emulsify or disrupt tissue, or to enhance drug delivery through sonoporation of cell membranes.

[0193] Alternatively, in other embodiments, cryogenic energy may be delivered through the needle assembly by circulating a cryogenic fluid such as nitrous oxide or liquid nitrogen through a lumen in the needle or through a dedicated cryoprobe channel adjacent to the needle. Cryotherapy applied through the needle may be used for cryocoagulation of choroidal vessels, for controlled tissue destruction, or for cryo preservation of tissue at the treatment site.

[0194] Alternatively, in other embodiments, resistive heating elements, such as a thin-film heater or a resistive wire coil disposed at or near the distal end of one or both needles, may also be used to deliver controlled thermal energy to tissue independently of or in addition to diathermy.

[0195] Each of these energy modalities may be controlled by the controller described herein and activated by user input such as a foot pedal and may include appropriate feedback sensors and safety interlocks to prevent excessive energy delivery.

[0196] It should be understood that certain features of the some of the embodiments described herein may be combined with one another in a new embodiment, For example, the needle drive assemblies that linearly advance and / or rotate the inner needle and / or the vibrating mechanism can be used in device embodiments that have a single needle for extending and retracting the single needle and / or vibrating the single needle and such assemblies and mechanisms are not only for use with an inner needle of a two-stage needle assembly. As another example, the tip bevel geometries described herein may be used for devices with a single needle, or for the inner needle and / or outer needle for a two-stage needle assembly or for the tip of a needle that is used to deploy a microneedle patch. Furthermore, in some device embodiment, the bevel tip geometry, two-stage needle assemblies and / or andmicroneedle patches may be used for a device that has a front or end-firing configuration as well as the side firing configurations describes herein.

[0197] In another aspect, in accordance with the teachings herein, in at least one embodiment the portion of the distal end of the needle which enters the subretinal space has a smaller diameter than the rest of the needle assembly in order to reduce the length of the bevel opening, reduce insertion force through the tissues, and minimize possible choroidal and retinal trauma. In at least one embodiment, this is achieved through concentrically nested needles. In at least one other embodiment, this is achieved by grinding the outside surface of the needle to create a tapered single needle with continuously varying outer diameter.

[0198] In another aspect, in accordance with the teachings herein, in at least one embodiment, the needle which enters the subretinal space has a combined conical and bevel tip geometry, creating a shorter bevel opening length configured to span only a single tissue layer at a time during penetration while maintaining sharpness of the needle.

[0199] In another aspect, in accordance with the teachings herein, in at least one embodiment, a control element is a provided which is an input wheel or control wheel that is actuatable by a user to provide to move the inner needle via a needle drive assembly, where the needle drive assembly comprises: helical gears, miter gears, screw gears, or bevel gears that enable coupled rotation in two 90 degree offset planes, where one gear is on the control wheel and the other gear is following such that its rotational axis is aligned with the direction of inner needle actuation motion; a lead screw which is attached to the inner needle is located and coupled by a nut in the following gear so that it moves axially through the following gear, wherein when the control wheel is turned the leading gear turns the follower gear and the nut at the center so that the lead screw and the inner needle move axially and push the inner needle through the outer needle.

[0200] In another aspect, in accordance with the teachings herein, there is provided at least one embodiment of a device for injecting and / or removing substances from a target, wherein the device comprises: a housing defining a main body and a distal end portion of the device; a needle that is moveable and disposed at the distal end portion of the device; a needle drive assembly that is coupled to the needle and is configured to cause the needle to simultaneously extend and rotate through a needle exit locationon a lateral surface of the distal end portion of the device at an angle to a longitudinal axis of the distal end portion of the device during needle deployment and a control element to control operation of the needle drive assembly. The needle may be a single needle or an inner needle in a two-stage needle arrangement.

[0201] In at least one embodiment, the control element is a controller to provide a user with electronic control for moving the inner needle, and the needle drive assembly further comprises: a motor / gearbox that has an output gear, the motor / gearbox being electrically coupled to and controlled by the controller; a driven gear that is coupled to the motor output gear, the driven gear having a threaded surface portion and a longitudinal channel in which the inner needle is located and fixedly attached; and a support block that is coupled to the housing, is coaxial with the driven gear and threaded surface portion and has a threaded channel through which the threaded portion is rotatingly engaged, wherein rotation of the motor gear causes the driven gear and threaded portion to rotate and move axially causing the inner needle to rotate as it moves axially during extension or retraction.

[0202] In at least one embodiment, the control element is a controller to provide a user with electronic control for moving the inner needle, and the needle drive assembly further comprises: a linear / rotary motor having a motor core, the linear / rotary motor being electrically coupled to and controlled by the controller; and two plain bushing support blocks for supporting the linear / rotary motor, wherein a portion of the inner needle runs through and is affixed to the motor core and rotation of the motor core causes the inner needle to rotate as it moves axially during extension or retraction.

[0203] It should be noted that the various device embodiments described herein for accessing certain regions of a target, such as the eye including the choroidal, suprachoroidal, retinal and subretinal regions, may be used to deliver treatment, such as drugs or other fluids or treatment elements (e.g., a microneedle patch), by including a vial or other elements with the device embodiments described herein. Examples of device embodiments with vials having treatment fluid are shown in FIGS. 12A to 17. However, the various device embodiments described herein may also be used to remove substances from these targets. In such cases, additional elements, such as an empty vial, and suction sources, such as reverse actuated plungers or pumps, may be used to remove substances. Examples of device embodiments where the vial may be empty and a reverse-actuatable plunger is used are also in FIGS. 12A to 17.

[0204] While the applicant's teachings described herein are in conjunction with various embodiments for illustrative purposes, it is not intended that the applicant's teachings be limited to such embodiments. On the contrary, the applicant's teachings described and illustrated herein encompass various alternatives, modifications, and equivalents, without generally departing from the embodiments described herein. For example, while the teachings described and shown herein may comprise certain elements / components and steps, modifications may be made as is known to those skilled in the art. For example, selected features from one or more of the example embodiments described herein in accordance with the teachings herein may be combined to create alternative embodiments that are not explicitly described. For example, as will be clear to a person having ordinary skill in the art, the devices and methods described herein may be implemented using other additional combinations and permutations of the various features and functions presented including shape, form factor, needle position or orientation, conduits, adjustments, controls, actuators, indicators, guidance elements, fluids and other materials, procedure steps, and applications. All values and sub-ranges within disclosed ranges are also disclosed. The subject-matter described herein intends to cover and embrace all suitable changes in technology.REFERENCES[1] D. W. Price etal., “Injection device for subretinal delivery of therapeutic agent,” US10806630B2, Oct. 20, 2020 Accessed: Apr. 28, 2025. [Online], Available: https: / / patents.google.com / patent / US 10806630B2 / en?q=(gyroscope+therapeutic s)&oq=gyroscope+therapeutics[2] A. Hejri et al., “A non-surgical method for subretinal delivery by trans-scleral microneedle injection,” Bioengineering & Translational Medicine, vol. 10, no. 3, p. e10755, 2025, doi: 10.1002 / btm2.10755.[3] M. S. Singh et al., “Development of an image-guided non-vitrectomy subretinal access approach for trans-scleral cell and gene therapy delivery,” Mar. 01, 2025, bloRxiv. doi: 10.1101 / 2025.02.25.640217.[4] A. C. Barnett, K. Wolkowicz, and J. Z. Moore, “Vibrating Needle Cutting Force,” presented at the ASME 2014 International Manufacturing Science and Engineering Conference collocated with the JSME 2014 International Conference on Materials and Processing and the 42nd North American Manufacturing Research Conference, American Society of Mechanical Engineers Digital Collection, Oct. 2014. doi: 10.1115 / MSEC2014-4049.[5] S. T. R. Gidde, A. Ciuciu, N. Devaravar, R. Doracio, K. Kianzad, and P. Hutapea, “Effect of vibration on insertion force and deflection of bioinspired needle in tissues,” Bioinspir. Biomim., vol. 15, no. 5, p. 054001, Jul. 2020, doi:10.1088 / 1748-3190 / ab9341.[6] Y. C. Huang, M. C. Tsai, and C. H. Lin, “A piezoelectric vibration-based syringe for reducing insertion force,” IOP Conf. Ser: Mater. Scl. Eng., vol. 42, p. 012020, Dec. 2012, doi: 10.1088 / 1757-899X / 42 / 1 / 012020.[7] K. K. Kundan and A. Ghatak, “Coupled Effect of Axial Velocity of Insertion and Vibration of a Hypodermic Needle Puncturing into a Soft Brittle Solid,” Biomedical Materials & Devices, vol. 2, no. 1, pp. 454-460, Mar. 2024, doi: 10.1007 / s44174- 023-00096-7.[8] M. Ferrara, G. Lugano, M. T. Sandinha, V. R. Kearns, B. Geraghty, and D. H. W.Steel, “Biomechanical properties of retina and choroid: a comprehensive review of techniques and translational relevance,” Eye, vol. 35, no. 7, pp. 1818-1832, Jul. 2021, doi: 10.1038 / S41433-021-01437-w.

Claims

CLAIMS:

1. A device for injecting into and / or removing substances from a target, wherein the device comprises:a housing defining a main body with a first longitudinal axis and a distal end portion of the device having a second longitudinal axis;a two-stage needle that is in the housing and moveable for deployment at the distal end portion of the device, the two-stage needle having an inner needle and an outer needle, the inner needle being disposed within the outer needle; anda needle drive assembly that is coupled to the two-stage needle, the needle drive assembly being configured to cause the outer needle to extend through a needle exit location on a lateral contact surface of the distal end portion of the device at an angle to the longitudinal axis of the distal end portion of the device, and to cause the inner needle to extend through the outer needle during needle deployment.

2. The device of claim 1 , wherein the needle drive assembly comprises:a primary control element that is actuatable by a user; anda needle holding member that is disposed within the housing and movably coupled to the primary control element, the needle holding member being adapted to hold the outer needle and being moveable during needle deployment to move the outer needle when the primary control element is actuated by the user to extend and retract the outer needle.

3. The device of claim 2, wherein the needle holding member is moveable about a pivot point that is an actual pivot or a virtual pivot and wherein the pivot point is located such that a portion of a perimeter of a circle that is concentric with the pivot point is tangent to the outer needle and coincident to an entry point where the outer needle enters the target.

4. The device of any one of claims 1 to 3, wherein the inner needle and the outer needle are independently moveable.

5. The device of any one of claims 1 to 4, wherein the target is a subretinal space of an eye and, during use, the outer needle is extended to penetrate a scleral layer of the eye to push against a choroid of the eye, the inner needle is then extended through the outer needle to penetrate through the choroid of the eye into the subretinal space,the outer needle is then retracted, and the inner needle is then advanced within the subretinal space before injection and / or removal.

6. The device of any one of claims 1 to 5, wherein a distal end portion of the inner needle is pre-curved, the inner needle optionally being made of a super-elastic material which is heat set to a curved shape, allowing it to be straight when retracted inside the outer needle and return to its curved shape upon deployment outside of the outer needle, wherein the super-elastic material is optionally nitinol.

7. The device of any one of claims 1 to 6, wherein an insulating material is disposed between the inner needle and the outer needle to electrically isolate the inner needle from the outer needle, the insulating material comprising an insulating sleeve, a coating, or a combination thereof.

8. The device of claim 7, wherein the inner needle and the outer needle are electrically coupled to a voltage generator to operate as a bipolar electrode pair for delivering high-frequency electrical energy at tips of the needles during bipolar diathermy where current flows from one of the needles through intervening tissue and returns via another of the needles.

9. The device of any one of claims 7 to 8, wherein the voltage generator is configured to apply diathermy energy before or during needle advancement through scleral or choroidal tissue for preconditioning thereby facilitating easier passage for at least one of the needles through the preconditioned tissue.

10. The device of any one of claims 7 to 9, wherein the device is operable in a bipolar diathermy mode or a monopolar diathermy mode, wherein during monopolar diathermy one of the inner needle and the outer needle is adapted to be an active electrode and a dispersive return electrode is positioned at a remote location on the patient’s body.

11. The device of any one of claims 1 to 10, wherein the needle drive assembly comprises a secondary control wheel that is user actuatable, a follower free-spinning backup wheel that rotates on an axle attached to a body of the device, and a friction drive wheel that is coupled to the secondary control wheel and spaced apart from the follower free-spinning backup wheel so that a proximal portion of the inner needle is slidably received between the follower free-spinning backup wheel and the frictiondrive wheel so that actuation of the secondary control wheel moves the inner needle within the outer needle.

12. The device of any one of claims 1 to 10, wherein the needle drive assembly comprises a secondary control wheel that is user actuatable, a gear that is attached to or integral with the secondary control wheel, a follower gear that interfaces with the gear at the control wheel and has a nut at a center of the follower gear, and a lead screw having a conduit through which a proximal portion of the inner needle is coupled so that the inner needle moves as the lead screw moves, wherein the nut is disposed to travel on the lead screw, wherein when the second control wheel is turned the gear at the control wheel imparts rotation on the follower gear and the nut at the center of the follower gear causes the lead screw and the inner needle to move axially.

13. The device of any one of claims 1 to 10, comprising a secondary control wheel that is user actuatable to move the inner needle, and the needle drive assembly further comprises:a follower free-spinning backup wheel that rotates on an axle attached to a body of the device;a friction drive wheel that is coupled to the control wheel;a pushing body that is slidably disposed between the free-spinning backup wheel and the friction drive wheel and having a helical thread on its outer cylindrical surface;a back-drivable screw or cam follower that is coupled to and downstream of the pushing body; anda nut or cam attached to the device body and in contact with the back-drivable screw,wherein the back-drivable screw is caused to rotate by the nut or the cam when the back-drivable screw is axially moved by the friction drive wheel when rotated by the control wheel, andwherein the inner needle is attached to the back-drivable screw or the cam follower so that the inner needle will move axially and twist when actuated by the screw or the cam follower.

14. The device of any one of claims 1 to 10, further comprising a secondary control wheel that is user actuatable and coupled to a helical gear tooth wheel and the needledrive assembly further comprises: a driven helical gear that is coupled to the helical gear tooth wheel such that the driven helical gear and the helical gear tooth wheel are right-angle helical gears and the driven helical gear is coupled to a back-drivable screw and nut with the inner needle being coupled to the driven helical gear and the back-drivable screw such that rotation of the secondary control drives the inner needle both axially and rotationally.

15. The device of any one of claims 1 to 10, wherein the needle drive assembly comprises a motor that is electrically coupled to and controlled by a controller, wherein the motor is configured to drive the inner needle axially and / or rotationally during extension or retraction.

16. The device of claim 15, wherein a drive gear of the needle drive assembly has an involute spline and the motor has an output with a pinion gear that is adapted to engage the involute spline.

17. The device of claim 15, wherein the motor has an output gear that is coupled to a driven gear having a coupled screw body that passes through a stationary support block with a threaded channel and the inner needle is axially coupled to the coupled screw body so that rotation of the output gear causes the coupled screw body to translate axially while simultaneously rotating, thereby advancing and rotating the inner needle.

18. The device of any one of claims 1 to 17, wherein the needle drive assembly is configured to simultaneously rotate and axially advance the inner needle during deployment, such that the inner needle follows a helical path as it is extended or retracted.

19. The device of claim 18, wherein the distal end portion of the inner needle has a needle tip geometry which is axially symmetric.

20. The device of any one of claims 1 to 19, further comprising a vial, a plunger that is in fluid communication with the vial and a motor that controls the plunger motion, wherein during use a proximal end of the inner needle is adapted to penetrate the vial and transport a treatment fluid to the inner needle when the vial contains the treatment fluid or remove a substance from the target and transport the substance to the vial when the vial is empty.

21. The device of any one of claims 1 to 19, wherein a proximal end portion of the inner needle is fluidically coupled to a vial to receive a treatment fluid to deliver when the distal end portion of the inner needle is deployed.

22. The device of any claim 20 or 21 , wherein an upper region of the inner needle has a flexural section allowing for a proximal end of the inner needle to be fixed in place.

23. The device of any one of claims 1 to 22, wherein the device comprises a trocar or blade at a distal end of the device for performing an incision while the device is moved into position before the outer needle or the inner needle is deployed.

24. The device of any one of claims 1 to 23, wherein the device comprises a vibrating element that is configured to apply a vibration to a distal needle portion of the inner or outer needles.

25. The device of any one of claims 1 to 24, wherein a bevel of a needle tip of the inner needle is oriented away from a center of the target prior to the needle tip penetrating a surface of the target, and as the inner needle tip penetrates the surface of the target, the bevel is rotated to be oriented towards the center of the target.

26. The device of claims 1 to 25, wherein the device is configured to provide cryotherapy, or other energy delivery through the inner needle and / or the outer needle.

27. A device for trans-scleral access to the eye of a patient, the device comprising:a housing defining a main body and a distal end portion;at least one needle that is movable for deployment at the distal end portion of the housing to penetrate through a scleral layer of the eye to access an internal target of the eye;and a needle drive assembly coupled to the at least one needle and configured to cause the at least one needle to extend through a needle exit location on a lateral contact surface of the distal end portion of the housing,wherein the at least one needle is conductive and coupled to an energy source that is configured to deliver energy through or from the at least one needle to coagulate, modify, or ablate tissue adjacent to an exposed conductive portion of the at least one needle that has been deployed to penetrate the eye.

28. The device of claim 27, wherein the at least one needle is coupled to the energy source to provide monopolar diathermy, wherein the at least one needle is configured as an active electrode for delivering high-frequency electrical energy to the tissue, and a dispersive return electrode is positioned ata remote location on a body of the patient.

29. The device of claim 27 or 28, wherein the energy source is configured to provide radiofrequency energy to the exposed conductive portion of the at least one needle to achieve the tissue ablation, coagulation, or modification.

30. The device of any one of claims 27 to 29, wherein the device comprises a laser fiber or waveguide routed through a lumen of the at least one needle that is coupled to the energy source to deliver laser energy to the tissue at the exposed conductive portion of the at least one needle for photocoagulation or tissue cutting.

31. The device of any one of claims 27 to 30, further comprising a vibrating element coupled to a needle holding memberthat is disposed within the housing and is coupled to the at least one needle, the vibrating element being configured to induce oscillations in the needle holding member that are transmitted to a distal portion of the at least one needle, the oscillations being semi-axial vibrations that facilitate penetration of the tip of the at least one needle through tissue.

32. The device of claim 31 , wherein the vibrating element comprises a piezoelectric transducer coupled to the needle holding member, the piezoelectric transducer being configured to deliver ultrasonic energy through the at least one needle to facilitate tissue penetration or enhance drug delivery through sonoporation.

33. The device of any one of claims 27 to 32, wherein the device comprises a cryogenic cooling element disposed within the housing and thermally coupled to a proximal or intermediate portion of the at least one needle to provide cooling thereto so that the at least one needle thermally conducts cryogenic thermal energy to tissue at or near a tip of the at least one needle for cryocoagulation of vessels at a needle entry site during use.

34. The device of any one of claims 27 to 33, wherein the device comprises a resistive heating element disposed at or near a distal end of the at least one needle for delivering controlled thermal energy to tissue adjacent to the distal end of the at least one needle.

35. The device of any one of claims 27 to 34, wherein energy delivered through the distal end portion of the at least one needle alters mechanical properties of tissue thereat to reduce mechanical resistance to needle deployment into the tissue.

36. A device for penetrating into a target at a posterior region of the eye, the device comprising:a housing defining a main body and a distal end portion;at least one needle that is moveable and deployed at the distal end portion in a side-firing configuration;a needle drive assembly coupled to the at least one needle and configured to cause the at least one needle to extend through a needle exit location on a lateral surface of the distal end portion of the device; andan end effector for conjunctiva management during use, the end effector being disposed at or near the distal end portion of the device for displacing or incising the conjunctiva to allow for passage of the distal end portion of the device to more posterior regions of the eye before the at least one needle is deployed.

37. The device of claim 36, wherein the end effector comprises a trocar integrated into the distal end portion of the housing, the trocar being shaped as one of a pyramidal trocar, a conical trocar, or a conical trocar with a flat face.

38. The device of claim 37, wherein the trocar has a length of approximately 1 to 10 mm.

39. The device of claim 36, wherein the end effector comprises a blade that is moveable at a distal tip of the device between an extended position and a retracted position using an actuator that is mechanically coupled to the blade.

40. The device of claim 39, wherein the blade is oriented so that a flat plane of the blade is tangent with the eye to reduce likelihood of cutting a sclera of the eye or an eyelid of the eye.

41. The device of claim 39 or 41, further comprising a spring-loaded cover at the distal tip of the device, wherein the cover is deflected to expose the blade when the device tip is pressed against the conjunctiva and the cover returns to a rest position to conceal the blade when a force is removed from the device tip.

42. The device of claim 36, wherein the end effector comprises a suction element for lifting a portion of the conjunctiva and a cutting element for incising the lifted conjunctiva.

43. The device of claim 36, wherein the end effector is an expandable trocar that is separate from the housing of the device, has a sharp distal tip and a flexible expandable body with a lumen wherein the flexible expandable body has a collapsed configuration for initial puncturing of the conjunctiva with the sharp distal tip and an expanded configuration after the initial puncturing occurs during which the flexible expandable portion is radially expanded when the distal end portion of the device is inserted through the lumen.

44. The device of claim 43, wherein the trocar is adapted to remain stationary relative to the conjunctiva after the initial puncturing and during passage of the distal end portion of the device, and the sharp tip of the trocar is sized to result in a smaller residual wound in the conjunctiva compared to a direct incision sized for the distal end portion of the device.

45. The device of claim 43 or 44, wherein the flexible expandable portion comprises a stent-like structure made from a shape-memory alloy exhibiting superelastic behavior to return to the collapsed configuration upon withdrawal of the distal end portion from the trocar.

46. A needle for insertion into a target, wherein the needle comprises:a shaft having an inner lumen; anda tip at a distal end of the shaft, the tip having a needle tip geometry such that a bevel opening is shaped so that a bevel opening length spans only a single tissue layer at a time at the target after needle deployment.

47. The device of claim 46, wherein the needle tip has a combined conical and bevel needle tip geometry, creating a shorter bevel opening length while maintaining a sharp tip for tissue penetration.

48. The device of claim 46, wherein the needle tip geometry has sidewalls with a conical shape, a closed end and one or more holes or ports at one or more side locations sidewalls so that the needle tip only allows for fluid flow at the one or more holes or ports.

49. The device of any one of claims 46 to 48, wherein the at least one needle comprises an outer needle and an inner needle disposed within the outer needle, and the needle tip geometry is at the distal end of the inner needle.

50. The device of any one of claims 1 to 49, wherein the target is a portion of the eye including the suprachoroidal or sub-retinal region.

51. A use of a device for treatment of a suprachoroidal or sub-retinal region of an eye, wherein the device is defined according to any one of claims 1 to 49.